Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Recipient ID:

Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Recipient Demographics Questions: 1 - 5

Country of primary residence1

Specify:2

State of residence of recipient:3

(for residents of USA)

Race (1) Questions: 4 - 5

Race4

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

Race detail5

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 6 - 14

Specify blood type

A B AB O

6

(For allogeneic HCTs only)

Specify Rh factor

Positive Negative

7

(For allogeneic HCTs only)

Does the recipient have a history of smoking cigarettes?

yes no Unknown

8

Has the recipient smoked cigarettes within the past year?

yes no Unknown

9

Has the recipient smoked cigarettes prior to but not during the past year?

yes no Unknown

10

Number of years

Known Unknown

11

Number of years:12

Average number of packs per day

Known Unknown

13

Average number of packs per day:14

Organ Function Prior to the Preparative Regimen (Conditioning) Questions: 15 - 38

AST (SGOT)

Known Unknown

15

16 U/L µkat/L

Date sample collected:17 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:18 U/L µkat/L

Total serum bilirubin

Known Unknown

19

20 mg/dL µmol/L

Date sample collected:21 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:22 mg/dL µmol/L

LDH

Known Unknown

23

24 U/L µkat/L

Date sample collected:25 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:26 U/L µkat/L

Serum creatinine

Known Unknown

27

28 mg/dL mmol/L µmol/L

Date sample collected:29 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:30 mg/dL mmol/L µmol/L

Total serum ferritin

Known Unknown

31

32 ng/mL (µg/L)

Date sample collected:33 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:34 ng/mL (µg/L)

Serum albumin

Known Unknown

35

36 g/dL g/L

Date sample collected:37 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:38 g/dL g/L

Hematologic Findings Prior to the Preparative Regimen (Conditioning) Questions: 39 - 54

Date CBC tested:39 __ __ __ __ - __ __- __ __

WBC

Known Unknown

40

41 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

42

43 %

Lymphocytes

Known Unknown

44

45 %

Hemoglobin

Known Unknown

46

47 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

48

Hematocrit

Known Unknown

49

50 %

Was RBC transfused < 30 days before date of test?

yes no

51

Platelets

Known Unknown

52

53 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused < 7 days before date of test?

yes no

54

Infection Questions: 55 - 75

Did the recipient have a history of clinically significant fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

55

Did the recipient have more than one fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

56

Fungal Infection (1) Questions: 57 - 63

Date of onset:57 __ __ __ __ - __ __- __ __

Select organism from list below58

210 Aspergillus, NOS

211 Aspergillus flavus

212 Aspergillus fumigatus

213 Aspergillus niger

215 Aspergillus terreus

214 Aspergillus ustus

270 Blastomyces (dermatitidis)

201 Candida albicans

208 Candida non-albicans

271 Coccidioides (all species)

222 Cryptococcus gattii

221 Cryptococcus neoformans

230 Fusarium (all species)

261 Histoplasma (capsulatum)

241 Mucorales (all species)

260 Pneumocystis (PCP / PJP)

242 Rhizopus (all species)

272 Scedosporium (all species)

240 Zygomycetes, NOS

503 Suspected fungal infection

Specify organism:59

Select site(s) from list below60

Select site(s) from list below61

Select site(s) from list below62

Was this fungal infection active within 2 weeks prior to the preparative regimen?

yes no

63

HTLV1 antibody

Reactive Non-reactive Inconclusive Not done

64

Cytomegalovirus antibody

Reactive Non-reactive Inconclusive Not done

65

Anti-EBV (Epstein-Barr virus antibody)

Positive Negative Inconclusive Not done

66

Hepatitis B surface antibody

Reactive Non-reactive Inconclusive Not done

67

Anti HBc: (hepatitis B core antibody)68

Reactive -For hepatitis tests that have a reactive result, also complete HEP form. 

Non-reactive

Not done

HBsAg: (hepatitis B surface antigen)69

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Not done

Hepatitis B — DNA70

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Anti-HCV: (hepatitis C antibody)71

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis C – NAT72

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis A antibody

Reactive Non-reactive Inconclusive Not done

73

HIV antibody

Positive Negative Inconclusive Not done Not reported

74

HIV – NAT

Positive Negative Inconclusive Not done Not reported

75

Pre-HCT Preparative Regimen (Conditioning) Questions: 76 - 247

Was a pre-HCT preparative regimen given?

yes no

76

Specify protocol intent77

(check only one) (Allogeneic HCTs only)

all agents given as outpatient

some, but not all, agents given as inpatient

all agents given as inpatient

Date pre-HCT preparative regimen
(irradiation or drugs) began:

78 __ __ __ __ - __ __- __ __

Use the earliest date from questions 82 (radiation) or 109-176 and 193-241 (systemic therapy).  Additional radiation and/or intrathecal
chemotherapy start dates may be prior to the date the preparative regimen began.  

Was irradiation performed as part of the pre-HCT preparative regimen?

yes no

79

What was the radiation field?80

total body

total body by tomotherapy

total lymphoid or nodal regions

thoracoabdominal region

Total dose:81

(dose per fraction x total number of fractions)

Gy cGy

Date started:82 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

83

Dose per fraction:84 Gy cGy

Number of days:85

(include "rest" days)

Total number of fractions:86

Was additional radiation given to other sites within 14 days of the pre-HCT preparative regimen?

yes no

87

CNS

yes no

88

Total dose:89 Gy cGy

Date started:90 __ __ __ __ - __ __- __ __

Gonadal

yes no

91

Total dose:92 Gy cGy

Date started:93 __ __ __ __ - __ __- __ __

Splenic

yes no

94

Total dose:95 Gy cGy

Date started:96 __ __ __ __ - __ __- __ __

Site of residual tumor

yes no

97

Total dose:98 Gy cGy

Date started:99 __ __ __ __ - __ __- __ __

Specify site:100

Other site

yes no

101

Total dose:102 Gy cGy

Date started:103 __ __ __ __ - __ __- __ __

Specify other site:104

Were drugs given for pre-HCT preparative regimen?

yes no

105

Dosing body weight used for pre-HCT preparative regimen (adjusted body weight):106 pounds kilograms

ALG, ALS, ATG, ATS

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Specify source

Horse Rabbit Other

110

Specify other source:111

Anthracycline

yes no

112

Daunorubicin

yes no

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

116

Total dose:117 mg

Date started:118 __ __ __ __ - __ __- __ __

Idarubicin

yes no

119

Total dose:120 mg

Date started:121 __ __ __ __ - __ __- __ __

Rubidazone

yes no

122

Total dose:123 mg

Date started:124 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

125

Total dose:126 mg

Date started:127 __ __ __ __ - __ __- __ __

Specify other anthracycline:128

Bleomycin (BLM, Blenoxane)

yes no

129

Total dose:130 mg

Date started:131 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

135

Carboplatin

yes no

136

Total dose:137 mg

Date started:138 __ __ __ __ - __ __- __ __

Cisplatin (Platinol, CDDP)

yes no

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

145

(excluding anti-nausea medication)

Methylprednisolone (Solu-Medrol)

yes no

146

Total dose:147 mg

Date started:148 __ __ __ __ - __ __- __ __

Prednisone

yes no

149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Specify other corticosteroid:158

Cyclophosphamide (Cytoxan)

yes no

159

Total dose:160 mg

Date started:161 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

162

Total dose:163 mg

Date started:164 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

165

Total dose:166 mg

Date started:167 __ __ __ __ - __ __- __ __

Fludarabine

yes no

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Intrathecal therapy

yes no

177

Intrathecal cytarabine (IT Ara-C)

yes no

178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

184

Total dose:185 mg

Date started:186 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

187

Total dose:188 mg

Date started:189 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:190

Melphalan (L-Pam)

yes no

191

Total dose:192 mg

Date started:193 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

194

Mitoxantrone (Novantrone)

yes no

195

Total dose:196 mg

Date started:197 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

198

Radio labeled MAb

yes no

199

Total dose of radioactive component:200 mCi MBq

Date started:201 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

202

Ibritumomab tiuxetan (Zevalin)

yes no

203

Other radio labeled MAb

yes no

204

Specify other radio labeled MAb:205

Alemtuzumab (Campath)

yes no

206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

209

Total dose:210 mg

Date started:211 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

212

Total dose:213 mg

Date started:214 __ __ __ __ - __ __- __ __

Other MAb

yes no

215

Total dose:216 mg

Date started:217 __ __ __ __ - __ __- __ __

Specify other MAb:218

Nitrosourea

yes no

219

Carmustine (BCNU)

yes no

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Specify other nitrosourea:229

Paclitaxel (Taxol, Xyotax)

yes no

230

Total dose:231 mg

Date started:232 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Thiotepa

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Other drug

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Specify other drug:242

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

243

Busulfan

yes no

244

Carboplatin

yes no

245

Other drug

yes no

246

Specify other drug:247

Socioeconomic Information Questions: 248 - 264

Is the recipient an adult (18 years of age or older) or emancipated minor?

yes no

248

Specify the recipient’s marital status249

single, never married

married or living with a partner

separated

divorced

widowed

Unknown

Specify the category which best describes the recipient’s current occupation250
(If the recipient is not currently employed, check the box which best describes his/her last job.)

Professional, technical, or related occupation (e.g., teacher/professor, nurse/physician, lawyer, engineer)

Manager, administrator, or proprietor (e.g., sales manager, real estate agent, postmaster)

Clerical or related occupation (e.g., secretary, clerk, mail carrier)

Sales occupation (e.g., sales associate, demonstrator, agent, broker)

Service occupation (e.g., police officer, cook, hairdresser)

Skilled craft or related occupation (e.g., carpenter, repair technician, telephone line worker)

Equipment / vehicle operator or related occupation (e.g., driver, railroad brakeman, sewer worker)

Laborer (e.g., helper, longshoreman, warehouse worker)

Farmer (e.g., owner, manager, operator, tenant)

Member of the military

Homemaker

Student

Under school age

Not previously employed

Unknown

Other

Specify other occupation:251

What is the recipient’s current or most recent work status prior to illness?252

Full time

Part time, by choice and not due to illness

Part time, due to illness

Unemployed, by choice and not due to illness

Unemployed, due to illness

Medical disability

Retired

Unknown

What is the highest educational grade the recipient completed?253

No primary education / under school age: No schooling (US Equivalent: Less than 1st Grade Education)

Less than primary or elementary education: Some formal schooling, but less than a complete primary or elementary education (US Equivalent: More than 1st grade
education, but less than 6th grade education)

Primary or elementary education: Beginning at age 5-7 and continuing for about 4-6 years (US Equivalent: Starts with 1st grade and ends with 6th grade)

Lower secondary education: Beginning at about age 11-12 and continuing for about 2-3 years (US Equivalent: Starts with 7th grade and typically ends with 9th grade)

Upper secondary education: Beginning at about age 15-16 and continuing for about 3 years (US Equivalent: Starts with 10th grade and ends with 12th grade)

Post-secondary, non-tertiary education: Programs lasting 6 months - 2 years (US Equivalent: Vocational programs of study)

Tertiary education, Type A: Programs that provide education that is largely theoretical, lasting 3-4 years (US Equivalent: Includes university programs that last 4 years and
lead to the award of a bachelor's degree, and university programs that lead to a master's degree)

Tertiary education, Type B: Programs that focus on practical, technical or occupational skills with a minimum duration of 2 years of full-time enrollment (US Equivalent:
Programs typically offered at community colleges that lead to an associate's degree)

Advanced research qualification: Programs that lead to the award of an advanced post-graduate degree, such as a Ph.D. (US Equivalent: Programs devoted to advanced

study and original research)

Is the recipient currently in school, or was enrolled prior to illness?

yes no Unknown

254

Is the recipient covered by health insurance?

yes no

255

Government-sponsored Medicaid

yes no

256

(U.S.)

Government-sponsored Medicare

yes no

257

(U.S.)

Government-sponsored National Health Insurance

yes no

258

(non U.S.)

Government­sponsored Veteran’s Affairs / military

yes no

259

Private health insurance (premium paid by individual) or group health insurance

yes no

260

Employer-sponsored disability insurance

yes no

261

Other

yes no

262

Specify other health insurance:263

Specify the recipient’s combined household gross annual income264
(Include earnings by all family members living in the household, before taxes.) (For U.S. residents only)

Less than $20,000

$20,000–$39,999

$40,000–$59,999

$60,000–$79,999

$80,000–$99,999

$100,000 and over

Recipient declines to provide this information

Unknown

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Testing for evidence of prior viral exposure/infection

Specify radiation field:

Specify radio labeled MAb:

Specify drugs:

Specify type of health insurance:

Center: CRID: 

Form 2000 R4.0: Recipient Baseline Data

CIBMTR Form 2000 revision 4.0 last updated Monday, August 14, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Recipient ID:

Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Recipient Demographics Questions: 1 - 5

Country of primary residence1

Specify:2

State of residence of recipient:3

(for residents of USA)

Race (1) Questions: 4 - 5

Race4

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

Race detail5

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 6 - 14

Specify blood type

A B AB O

6

(For allogeneic HCTs only)

Specify Rh factor

Positive Negative

7

(For allogeneic HCTs only)

Does the recipient have a history of smoking cigarettes?

yes no Unknown

8

Has the recipient smoked cigarettes within the past year?

yes no Unknown

9

Has the recipient smoked cigarettes prior to but not during the past year?

yes no Unknown

10

Number of years

Known Unknown

11

Number of years:12

Average number of packs per day

Known Unknown

13

Average number of packs per day:14

Organ Function Prior to the Preparative Regimen (Conditioning) Questions: 15 - 38

AST (SGOT)

Known Unknown

15

16 U/L µkat/L

Date sample collected:17 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:18 U/L µkat/L

Total serum bilirubin

Known Unknown

19

20 mg/dL µmol/L

Date sample collected:21 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:22 mg/dL µmol/L

LDH

Known Unknown

23

24 U/L µkat/L

Date sample collected:25 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:26 U/L µkat/L

Serum creatinine

Known Unknown

27

28 mg/dL mmol/L µmol/L

Date sample collected:29 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:30 mg/dL mmol/L µmol/L

Total serum ferritin

Known Unknown

31

32 ng/mL (µg/L)

Date sample collected:33 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:34 ng/mL (µg/L)

Serum albumin

Known Unknown

35

36 g/dL g/L

Date sample collected:37 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:38 g/dL g/L

Hematologic Findings Prior to the Preparative Regimen (Conditioning) Questions: 39 - 54

Date CBC tested:39 __ __ __ __ - __ __- __ __

WBC

Known Unknown

40

41 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

42

43 %

Lymphocytes

Known Unknown

44

45 %

Hemoglobin

Known Unknown

46

47 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

48

Hematocrit

Known Unknown

49

50 %

Was RBC transfused < 30 days before date of test?

yes no

51

Platelets

Known Unknown

52

53 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused < 7 days before date of test?

yes no

54

Infection Questions: 55 - 75

Did the recipient have a history of clinically significant fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

55

Did the recipient have more than one fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

56

Fungal Infection (1) Questions: 57 - 63

Date of onset:57 __ __ __ __ - __ __- __ __

Select organism from list below58

210 Aspergillus, NOS

211 Aspergillus flavus

212 Aspergillus fumigatus

213 Aspergillus niger

215 Aspergillus terreus

214 Aspergillus ustus

270 Blastomyces (dermatitidis)

201 Candida albicans

208 Candida non-albicans

271 Coccidioides (all species)

222 Cryptococcus gattii

221 Cryptococcus neoformans

230 Fusarium (all species)

261 Histoplasma (capsulatum)

241 Mucorales (all species)

260 Pneumocystis (PCP / PJP)

242 Rhizopus (all species)

272 Scedosporium (all species)

240 Zygomycetes, NOS

503 Suspected fungal infection

Specify organism:59

Select site(s) from list below60

Select site(s) from list below61

Select site(s) from list below62

Was this fungal infection active within 2 weeks prior to the preparative regimen?

yes no

63

HTLV1 antibody

Reactive Non-reactive Inconclusive Not done

64

Cytomegalovirus antibody

Reactive Non-reactive Inconclusive Not done

65

Anti-EBV (Epstein-Barr virus antibody)

Positive Negative Inconclusive Not done

66

Hepatitis B surface antibody

Reactive Non-reactive Inconclusive Not done

67

Anti HBc: (hepatitis B core antibody)68

Reactive -For hepatitis tests that have a reactive result, also complete HEP form. 

Non-reactive

Not done

HBsAg: (hepatitis B surface antigen)69

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Not done

Hepatitis B — DNA70

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Anti-HCV: (hepatitis C antibody)71

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis C – NAT72

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis A antibody

Reactive Non-reactive Inconclusive Not done

73

HIV antibody

Positive Negative Inconclusive Not done Not reported

74

HIV – NAT

Positive Negative Inconclusive Not done Not reported

75

Pre-HCT Preparative Regimen (Conditioning) Questions: 76 - 247

Was a pre-HCT preparative regimen given?

yes no

76

Specify protocol intent77

(check only one) (Allogeneic HCTs only)

all agents given as outpatient

some, but not all, agents given as inpatient

all agents given as inpatient

Date pre-HCT preparative regimen
(irradiation or drugs) began:

78 __ __ __ __ - __ __- __ __

Use the earliest date from questions 82 (radiation) or 109-176 and 193-241 (systemic therapy).  Additional radiation and/or intrathecal
chemotherapy start dates may be prior to the date the preparative regimen began.  

Was irradiation performed as part of the pre-HCT preparative regimen?

yes no

79

What was the radiation field?80

total body

total body by tomotherapy

total lymphoid or nodal regions

thoracoabdominal region

Total dose:81

(dose per fraction x total number of fractions)

Gy cGy

Date started:82 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

83

Dose per fraction:84 Gy cGy

Number of days:85

(include "rest" days)

Total number of fractions:86

Was additional radiation given to other sites within 14 days of the pre-HCT preparative regimen?

yes no

87

CNS

yes no

88

Total dose:89 Gy cGy

Date started:90 __ __ __ __ - __ __- __ __

Gonadal

yes no

91

Total dose:92 Gy cGy

Date started:93 __ __ __ __ - __ __- __ __

Splenic

yes no

94

Total dose:95 Gy cGy

Date started:96 __ __ __ __ - __ __- __ __

Site of residual tumor

yes no

97

Total dose:98 Gy cGy

Date started:99 __ __ __ __ - __ __- __ __

Specify site:100

Other site

yes no

101

Total dose:102 Gy cGy

Date started:103 __ __ __ __ - __ __- __ __

Specify other site:104

Were drugs given for pre-HCT preparative regimen?

yes no

105

Dosing body weight used for pre-HCT preparative regimen (adjusted body weight):106 pounds kilograms

ALG, ALS, ATG, ATS

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Specify source

Horse Rabbit Other

110

Specify other source:111

Anthracycline

yes no

112

Daunorubicin

yes no

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

116

Total dose:117 mg

Date started:118 __ __ __ __ - __ __- __ __

Idarubicin

yes no

119

Total dose:120 mg

Date started:121 __ __ __ __ - __ __- __ __

Rubidazone

yes no

122

Total dose:123 mg

Date started:124 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

125

Total dose:126 mg

Date started:127 __ __ __ __ - __ __- __ __

Specify other anthracycline:128

Bleomycin (BLM, Blenoxane)

yes no

129

Total dose:130 mg

Date started:131 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

135

Carboplatin

yes no

136

Total dose:137 mg

Date started:138 __ __ __ __ - __ __- __ __

Cisplatin (Platinol, CDDP)

yes no

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

145

(excluding anti-nausea medication)

Methylprednisolone (Solu-Medrol)

yes no

146

Total dose:147 mg

Date started:148 __ __ __ __ - __ __- __ __

Prednisone

yes no

149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Specify other corticosteroid:158

Cyclophosphamide (Cytoxan)

yes no

159

Total dose:160 mg

Date started:161 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

162

Total dose:163 mg

Date started:164 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

165

Total dose:166 mg

Date started:167 __ __ __ __ - __ __- __ __

Fludarabine

yes no

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Intrathecal therapy

yes no

177

Intrathecal cytarabine (IT Ara-C)

yes no

178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

184

Total dose:185 mg

Date started:186 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

187

Total dose:188 mg

Date started:189 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:190

Melphalan (L-Pam)

yes no

191

Total dose:192 mg

Date started:193 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

194

Mitoxantrone (Novantrone)

yes no

195

Total dose:196 mg

Date started:197 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

198

Radio labeled MAb

yes no

199

Total dose of radioactive component:200 mCi MBq

Date started:201 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

202

Ibritumomab tiuxetan (Zevalin)

yes no

203

Other radio labeled MAb

yes no

204

Specify other radio labeled MAb:205

Alemtuzumab (Campath)

yes no

206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

209

Total dose:210 mg

Date started:211 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

212

Total dose:213 mg

Date started:214 __ __ __ __ - __ __- __ __

Other MAb

yes no

215

Total dose:216 mg

Date started:217 __ __ __ __ - __ __- __ __

Specify other MAb:218

Nitrosourea

yes no

219

Carmustine (BCNU)

yes no

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Specify other nitrosourea:229

Paclitaxel (Taxol, Xyotax)

yes no

230

Total dose:231 mg

Date started:232 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Thiotepa

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Other drug

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Specify other drug:242

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

243

Busulfan

yes no

244

Carboplatin

yes no

245

Other drug

yes no

246

Specify other drug:247

Socioeconomic Information Questions: 248 - 264

Is the recipient an adult (18 years of age or older) or emancipated minor?

yes no

248

Specify the recipient’s marital status249

single, never married

married or living with a partner

separated

divorced

widowed

Unknown

Specify the category which best describes the recipient’s current occupation250
(If the recipient is not currently employed, check the box which best describes his/her last job.)

Professional, technical, or related occupation (e.g., teacher/professor, nurse/physician, lawyer, engineer)

Manager, administrator, or proprietor (e.g., sales manager, real estate agent, postmaster)

Clerical or related occupation (e.g., secretary, clerk, mail carrier)

Sales occupation (e.g., sales associate, demonstrator, agent, broker)

Service occupation (e.g., police officer, cook, hairdresser)

Skilled craft or related occupation (e.g., carpenter, repair technician, telephone line worker)

Equipment / vehicle operator or related occupation (e.g., driver, railroad brakeman, sewer worker)

Laborer (e.g., helper, longshoreman, warehouse worker)

Farmer (e.g., owner, manager, operator, tenant)

Member of the military

Homemaker

Student

Under school age

Not previously employed

Unknown

Other

Specify other occupation:251

What is the recipient’s current or most recent work status prior to illness?252

Full time

Part time, by choice and not due to illness

Part time, due to illness

Unemployed, by choice and not due to illness

Unemployed, due to illness

Medical disability

Retired

Unknown

What is the highest educational grade the recipient completed?253

No primary education / under school age: No schooling (US Equivalent: Less than 1st Grade Education)

Less than primary or elementary education: Some formal schooling, but less than a complete primary or elementary education (US Equivalent: More than 1st grade
education, but less than 6th grade education)

Primary or elementary education: Beginning at age 5-7 and continuing for about 4-6 years (US Equivalent: Starts with 1st grade and ends with 6th grade)

Lower secondary education: Beginning at about age 11-12 and continuing for about 2-3 years (US Equivalent: Starts with 7th grade and typically ends with 9th grade)

Upper secondary education: Beginning at about age 15-16 and continuing for about 3 years (US Equivalent: Starts with 10th grade and ends with 12th grade)

Post-secondary, non-tertiary education: Programs lasting 6 months - 2 years (US Equivalent: Vocational programs of study)

Tertiary education, Type A: Programs that provide education that is largely theoretical, lasting 3-4 years (US Equivalent: Includes university programs that last 4 years and
lead to the award of a bachelor's degree, and university programs that lead to a master's degree)

Tertiary education, Type B: Programs that focus on practical, technical or occupational skills with a minimum duration of 2 years of full-time enrollment (US Equivalent:
Programs typically offered at community colleges that lead to an associate's degree)

Advanced research qualification: Programs that lead to the award of an advanced post-graduate degree, such as a Ph.D. (US Equivalent: Programs devoted to advanced
study and original research)

Is the recipient currently in school, or was enrolled prior to illness?

yes no Unknown

254

Is the recipient covered by health insurance?

yes no

255

Government-sponsored Medicaid

yes no

256

(U.S.)

Government-sponsored Medicare

yes no

257

(U.S.)

Government-sponsored National Health Insurance

yes no

258

(non U.S.)

Government­sponsored Veteran’s Affairs / military

yes no

259

Private health insurance (premium paid by individual) or group health insurance

yes no

260

Employer-sponsored disability insurance

yes no

261

Other

yes no

262

Specify other health insurance:263

Specify the recipient’s combined household gross annual income264
(Include earnings by all family members living in the household, before taxes.) (For U.S. residents only)

Less than $20,000

$20,000–$39,999

$40,000–$59,999

$60,000–$79,999

$80,000–$99,999

$100,000 and over

Recipient declines to provide this information

Unknown

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Testing for evidence of prior viral exposure/infection

Specify radiation field:

Specify radio labeled MAb:

Specify drugs:

Specify type of health insurance:

Center: CRID: 

Form 2000 R4.0: Recipient Baseline Data

CIBMTR Form 2000 revision 4.0 last updated Monday, August 14, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Recipient ID:

Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Recipient Demographics Questions: 1 - 5

Country of primary residence1

Specify:2

State of residence of recipient:3

(for residents of USA)

Race (1) Questions: 4 - 5

Race4

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

Race detail5

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 6 - 14

Specify blood type

A B AB O

6

(For allogeneic HCTs only)

Specify Rh factor

Positive Negative

7

(For allogeneic HCTs only)

Does the recipient have a history of smoking cigarettes?

yes no Unknown

8

Has the recipient smoked cigarettes within the past year?

yes no Unknown

9

Has the recipient smoked cigarettes prior to but not during the past year?

yes no Unknown

10

Number of years

Known Unknown

11

Number of years:12

Average number of packs per day

Known Unknown

13

Average number of packs per day:14

Organ Function Prior to the Preparative Regimen (Conditioning) Questions: 15 - 38

AST (SGOT)

Known Unknown

15

16 U/L µkat/L

Date sample collected:17 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:18 U/L µkat/L

Total serum bilirubin

Known Unknown

19

20 mg/dL µmol/L

Date sample collected:21 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:22 mg/dL µmol/L

LDH

Known Unknown

23

24 U/L µkat/L

Date sample collected:25 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:26 U/L µkat/L

Serum creatinine

Known Unknown

27

28 mg/dL mmol/L µmol/L

Date sample collected:29 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:30 mg/dL mmol/L µmol/L

Total serum ferritin

Known Unknown

31

32 ng/mL (µg/L)

Date sample collected:33 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:34 ng/mL (µg/L)

Serum albumin

Known Unknown

35

36 g/dL g/L

Date sample collected:37 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:38 g/dL g/L

Hematologic Findings Prior to the Preparative Regimen (Conditioning) Questions: 39 - 54

Date CBC tested:39 __ __ __ __ - __ __- __ __

WBC

Known Unknown

40

41 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

42

43 %

Lymphocytes

Known Unknown

44

45 %

Hemoglobin

Known Unknown

46

47 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

48

Hematocrit

Known Unknown

49

50 %

Was RBC transfused < 30 days before date of test?

yes no

51

Platelets

Known Unknown

52

53 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused < 7 days before date of test?

yes no

54

Infection Questions: 55 - 75

Did the recipient have a history of clinically significant fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

55

Did the recipient have more than one fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

56

Fungal Infection (1) Questions: 57 - 63

Date of onset:57 __ __ __ __ - __ __- __ __

Select organism from list below58

210 Aspergillus, NOS

211 Aspergillus flavus

212 Aspergillus fumigatus

213 Aspergillus niger

215 Aspergillus terreus

214 Aspergillus ustus

270 Blastomyces (dermatitidis)

201 Candida albicans

208 Candida non-albicans

271 Coccidioides (all species)

222 Cryptococcus gattii

221 Cryptococcus neoformans

230 Fusarium (all species)

261 Histoplasma (capsulatum)

241 Mucorales (all species)

260 Pneumocystis (PCP / PJP)

242 Rhizopus (all species)

272 Scedosporium (all species)

240 Zygomycetes, NOS

503 Suspected fungal infection

Specify organism:59

Select site(s) from list below60

Select site(s) from list below61

Select site(s) from list below62

Was this fungal infection active within 2 weeks prior to the preparative regimen?

yes no

63

HTLV1 antibody

Reactive Non-reactive Inconclusive Not done

64

Cytomegalovirus antibody

Reactive Non-reactive Inconclusive Not done

65

Anti-EBV (Epstein-Barr virus antibody)

Positive Negative Inconclusive Not done

66

Hepatitis B surface antibody

Reactive Non-reactive Inconclusive Not done

67

Anti HBc: (hepatitis B core antibody)68

Reactive -For hepatitis tests that have a reactive result, also complete HEP form. 

Non-reactive

Not done

HBsAg: (hepatitis B surface antigen)69

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Not done

Hepatitis B — DNA70

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Anti-HCV: (hepatitis C antibody)71

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis C – NAT72

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis A antibody

Reactive Non-reactive Inconclusive Not done

73

HIV antibody

Positive Negative Inconclusive Not done Not reported

74

HIV – NAT

Positive Negative Inconclusive Not done Not reported

75

Pre-HCT Preparative Regimen (Conditioning) Questions: 76 - 247

Was a pre-HCT preparative regimen given?

yes no

76

Specify protocol intent77

(check only one) (Allogeneic HCTs only)

all agents given as outpatient

some, but not all, agents given as inpatient

all agents given as inpatient

Date pre-HCT preparative regimen
(irradiation or drugs) began:

78 __ __ __ __ - __ __- __ __

Use the earliest date from questions 82 (radiation) or 109-176 and 193-241 (systemic therapy).  Additional radiation and/or intrathecal
chemotherapy start dates may be prior to the date the preparative regimen began.  

Was irradiation performed as part of the pre-HCT preparative regimen?

yes no

79

What was the radiation field?80

total body

total body by tomotherapy

total lymphoid or nodal regions

thoracoabdominal region

Total dose:81

(dose per fraction x total number of fractions)

Gy cGy

Date started:82 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

83

Dose per fraction:84 Gy cGy

Number of days:85

(include "rest" days)

Total number of fractions:86

Was additional radiation given to other sites within 14 days of the pre-HCT preparative regimen?

yes no

87

CNS

yes no

88

Total dose:89 Gy cGy

Date started:90 __ __ __ __ - __ __- __ __

Gonadal

yes no

91

Total dose:92 Gy cGy

Date started:93 __ __ __ __ - __ __- __ __

Splenic

yes no

94

Total dose:95 Gy cGy

Date started:96 __ __ __ __ - __ __- __ __

Site of residual tumor

yes no

97

Total dose:98 Gy cGy

Date started:99 __ __ __ __ - __ __- __ __

Specify site:100

Other site

yes no

101

Total dose:102 Gy cGy

Date started:103 __ __ __ __ - __ __- __ __

Specify other site:104

Were drugs given for pre-HCT preparative regimen?

yes no

105

Dosing body weight used for pre-HCT preparative regimen (adjusted body weight):106 pounds kilograms

ALG, ALS, ATG, ATS

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Specify source

Horse Rabbit Other

110

Specify other source:111

Anthracycline

yes no

112

Daunorubicin

yes no

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

116

Total dose:117 mg

Date started:118 __ __ __ __ - __ __- __ __

Idarubicin

yes no

119

Total dose:120 mg

Date started:121 __ __ __ __ - __ __- __ __

Rubidazone

yes no

122

Total dose:123 mg

Date started:124 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

125

Total dose:126 mg

Date started:127 __ __ __ __ - __ __- __ __

Specify other anthracycline:128

Bleomycin (BLM, Blenoxane)

yes no

129

Total dose:130 mg

Date started:131 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

135

Carboplatin

yes no

136

Total dose:137 mg

Date started:138 __ __ __ __ - __ __- __ __

Cisplatin (Platinol, CDDP)

yes no

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

145

(excluding anti-nausea medication)

Methylprednisolone (Solu-Medrol)

yes no

146

Total dose:147 mg

Date started:148 __ __ __ __ - __ __- __ __

Prednisone

yes no

149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Specify other corticosteroid:158

Cyclophosphamide (Cytoxan)

yes no

159

Total dose:160 mg

Date started:161 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

162

Total dose:163 mg

Date started:164 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

165

Total dose:166 mg

Date started:167 __ __ __ __ - __ __- __ __

Fludarabine

yes no

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Intrathecal therapy

yes no

177

Intrathecal cytarabine (IT Ara-C)

yes no

178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

184

Total dose:185 mg

Date started:186 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

187

Total dose:188 mg

Date started:189 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:190

Melphalan (L-Pam)

yes no

191

Total dose:192 mg

Date started:193 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

194

Mitoxantrone (Novantrone)

yes no

195

Total dose:196 mg

Date started:197 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

198

Radio labeled MAb

yes no

199

Total dose of radioactive component:200 mCi MBq

Date started:201 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

202

Ibritumomab tiuxetan (Zevalin)

yes no

203

Other radio labeled MAb

yes no

204

Specify other radio labeled MAb:205

Alemtuzumab (Campath)

yes no

206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

209

Total dose:210 mg

Date started:211 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

212

Total dose:213 mg

Date started:214 __ __ __ __ - __ __- __ __

Other MAb

yes no

215

Total dose:216 mg

Date started:217 __ __ __ __ - __ __- __ __

Specify other MAb:218

Nitrosourea

yes no

219

Carmustine (BCNU)

yes no

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Specify other nitrosourea:229

Paclitaxel (Taxol, Xyotax)

yes no

230

Total dose:231 mg

Date started:232 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Thiotepa

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Other drug

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Specify other drug:242

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

243

Busulfan

yes no

244

Carboplatin

yes no

245

Other drug

yes no

246

Specify other drug:247

Socioeconomic Information Questions: 248 - 264

Is the recipient an adult (18 years of age or older) or emancipated minor?

yes no

248

Specify the recipient’s marital status249

single, never married

married or living with a partner

separated

divorced

widowed

Unknown

Specify the category which best describes the recipient’s current occupation250
(If the recipient is not currently employed, check the box which best describes his/her last job.)

Professional, technical, or related occupation (e.g., teacher/professor, nurse/physician, lawyer, engineer)

Manager, administrator, or proprietor (e.g., sales manager, real estate agent, postmaster)

Clerical or related occupation (e.g., secretary, clerk, mail carrier)

Sales occupation (e.g., sales associate, demonstrator, agent, broker)

Service occupation (e.g., police officer, cook, hairdresser)

Skilled craft or related occupation (e.g., carpenter, repair technician, telephone line worker)

Equipment / vehicle operator or related occupation (e.g., driver, railroad brakeman, sewer worker)

Laborer (e.g., helper, longshoreman, warehouse worker)

Farmer (e.g., owner, manager, operator, tenant)

Member of the military

Homemaker

Student

Under school age

Not previously employed

Unknown

Other

Specify other occupation:251

What is the recipient’s current or most recent work status prior to illness?252

Full time

Part time, by choice and not due to illness

Part time, due to illness

Unemployed, by choice and not due to illness

Unemployed, due to illness

Medical disability

Retired

Unknown

What is the highest educational grade the recipient completed?253

No primary education / under school age: No schooling (US Equivalent: Less than 1st Grade Education)

Less than primary or elementary education: Some formal schooling, but less than a complete primary or elementary education (US Equivalent: More than 1st grade
education, but less than 6th grade education)

Primary or elementary education: Beginning at age 5-7 and continuing for about 4-6 years (US Equivalent: Starts with 1st grade and ends with 6th grade)

Lower secondary education: Beginning at about age 11-12 and continuing for about 2-3 years (US Equivalent: Starts with 7th grade and typically ends with 9th grade)

Upper secondary education: Beginning at about age 15-16 and continuing for about 3 years (US Equivalent: Starts with 10th grade and ends with 12th grade)

Post-secondary, non-tertiary education: Programs lasting 6 months - 2 years (US Equivalent: Vocational programs of study)

Tertiary education, Type A: Programs that provide education that is largely theoretical, lasting 3-4 years (US Equivalent: Includes university programs that last 4 years and
lead to the award of a bachelor's degree, and university programs that lead to a master's degree)

Tertiary education, Type B: Programs that focus on practical, technical or occupational skills with a minimum duration of 2 years of full-time enrollment (US Equivalent:
Programs typically offered at community colleges that lead to an associate's degree)

Advanced research qualification: Programs that lead to the award of an advanced post-graduate degree, such as a Ph.D. (US Equivalent: Programs devoted to advanced
study and original research)

Is the recipient currently in school, or was enrolled prior to illness?

yes no Unknown

254

Is the recipient covered by health insurance?

yes no

255

Government-sponsored Medicaid

yes no

256

(U.S.)

Government-sponsored Medicare

yes no

257

(U.S.)

Government-sponsored National Health Insurance

yes no

258

(non U.S.)

Government­sponsored Veteran’s Affairs / military

yes no

259

Private health insurance (premium paid by individual) or group health insurance

yes no

260

Employer-sponsored disability insurance

yes no

261

Other

yes no

262

Specify other health insurance:263

Specify the recipient’s combined household gross annual income264
(Include earnings by all family members living in the household, before taxes.) (For U.S. residents only)

Less than $20,000

$20,000–$39,999

$40,000–$59,999

$60,000–$79,999

$80,000–$99,999

$100,000 and over

Recipient declines to provide this information

Unknown

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Testing for evidence of prior viral exposure/infection

Specify radiation field:

Specify radio labeled MAb:

Specify drugs:

Specify type of health insurance:

Center: CRID: 

Form 2000 R4.0: Recipient Baseline Data

CIBMTR Form 2000 revision 4.0 last updated Monday, August 14, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Recipient ID:

Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Recipient Demographics Questions: 1 - 5

Country of primary residence1

Specify:2

State of residence of recipient:3

(for residents of USA)

Race (1) Questions: 4 - 5

Race4

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

Race detail5

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 6 - 14

Specify blood type

A B AB O

6

(For allogeneic HCTs only)

Specify Rh factor

Positive Negative

7

(For allogeneic HCTs only)

Does the recipient have a history of smoking cigarettes?

yes no Unknown

8

Has the recipient smoked cigarettes within the past year?

yes no Unknown

9

Has the recipient smoked cigarettes prior to but not during the past year?

yes no Unknown

10

Number of years

Known Unknown

11

Number of years:12

Average number of packs per day

Known Unknown

13

Average number of packs per day:14

Organ Function Prior to the Preparative Regimen (Conditioning) Questions: 15 - 38

AST (SGOT)

Known Unknown

15

16 U/L µkat/L

Date sample collected:17 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:18 U/L µkat/L

Total serum bilirubin

Known Unknown

19

20 mg/dL µmol/L

Date sample collected:21 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:22 mg/dL µmol/L

LDH

Known Unknown

23

24 U/L µkat/L

Date sample collected:25 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:26 U/L µkat/L

Serum creatinine

Known Unknown

27

28 mg/dL mmol/L µmol/L

Date sample collected:29 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:30 mg/dL mmol/L µmol/L

Total serum ferritin

Known Unknown

31

32 ng/mL (µg/L)

Date sample collected:33 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:34 ng/mL (µg/L)

Serum albumin

Known Unknown

35

36 g/dL g/L

Date sample collected:37 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:38 g/dL g/L

Hematologic Findings Prior to the Preparative Regimen (Conditioning) Questions: 39 - 54

Date CBC tested:39 __ __ __ __ - __ __- __ __

WBC

Known Unknown

40

41 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

42

43 %

Lymphocytes

Known Unknown

44

45 %

Hemoglobin

Known Unknown

46

47 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

48

Hematocrit

Known Unknown

49

50 %

Was RBC transfused < 30 days before date of test?

yes no

51

Platelets

Known Unknown

52

53 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused < 7 days before date of test?

yes no

54

Infection Questions: 55 - 75

Did the recipient have a history of clinically significant fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

55

Did the recipient have more than one fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

56

Fungal Infection (1) Questions: 57 - 63

Date of onset:57 __ __ __ __ - __ __- __ __

Select organism from list below58

210 Aspergillus, NOS

211 Aspergillus flavus

212 Aspergillus fumigatus

213 Aspergillus niger

215 Aspergillus terreus

214 Aspergillus ustus

270 Blastomyces (dermatitidis)

201 Candida albicans

208 Candida non-albicans

271 Coccidioides (all species)

222 Cryptococcus gattii

221 Cryptococcus neoformans

230 Fusarium (all species)

261 Histoplasma (capsulatum)

241 Mucorales (all species)

260 Pneumocystis (PCP / PJP)

242 Rhizopus (all species)

272 Scedosporium (all species)

240 Zygomycetes, NOS

503 Suspected fungal infection

Specify organism:59

Select site(s) from list below60

Select site(s) from list below61

Select site(s) from list below62

Was this fungal infection active within 2 weeks prior to the preparative regimen?

yes no

63

HTLV1 antibody

Reactive Non-reactive Inconclusive Not done

64

Cytomegalovirus antibody

Reactive Non-reactive Inconclusive Not done

65

Anti-EBV (Epstein-Barr virus antibody)

Positive Negative Inconclusive Not done

66

Hepatitis B surface antibody

Reactive Non-reactive Inconclusive Not done

67

Anti HBc: (hepatitis B core antibody)68

Reactive -For hepatitis tests that have a reactive result, also complete HEP form. 

Non-reactive

Not done

HBsAg: (hepatitis B surface antigen)69

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Not done

Hepatitis B — DNA70

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Anti-HCV: (hepatitis C antibody)71

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis C – NAT72

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis A antibody

Reactive Non-reactive Inconclusive Not done

73

HIV antibody

Positive Negative Inconclusive Not done Not reported

74

HIV – NAT

Positive Negative Inconclusive Not done Not reported

75

Pre-HCT Preparative Regimen (Conditioning) Questions: 76 - 247

Was a pre-HCT preparative regimen given?

yes no

76

Specify protocol intent77

(check only one) (Allogeneic HCTs only)

all agents given as outpatient

some, but not all, agents given as inpatient

all agents given as inpatient

Date pre-HCT preparative regimen
(irradiation or drugs) began:

78 __ __ __ __ - __ __- __ __

Use the earliest date from questions 82 (radiation) or 109-176 and 193-241 (systemic therapy).  Additional radiation and/or intrathecal
chemotherapy start dates may be prior to the date the preparative regimen began.  

Was irradiation performed as part of the pre-HCT preparative regimen?

yes no

79

What was the radiation field?80

total body

total body by tomotherapy

total lymphoid or nodal regions

thoracoabdominal region

Total dose:81

(dose per fraction x total number of fractions)

Gy cGy

Date started:82 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

83

Dose per fraction:84 Gy cGy

Number of days:85

(include "rest" days)

Total number of fractions:86

Was additional radiation given to other sites within 14 days of the pre-HCT preparative regimen?

yes no

87

CNS

yes no

88

Total dose:89 Gy cGy

Date started:90 __ __ __ __ - __ __- __ __

Gonadal

yes no

91

Total dose:92 Gy cGy

Date started:93 __ __ __ __ - __ __- __ __

Splenic

yes no

94

Total dose:95 Gy cGy

Date started:96 __ __ __ __ - __ __- __ __

Site of residual tumor

yes no

97

Total dose:98 Gy cGy

Date started:99 __ __ __ __ - __ __- __ __

Specify site:100

Other site

yes no

101

Total dose:102 Gy cGy

Date started:103 __ __ __ __ - __ __- __ __

Specify other site:104

Were drugs given for pre-HCT preparative regimen?

yes no

105

Dosing body weight used for pre-HCT preparative regimen (adjusted body weight):106 pounds kilograms

ALG, ALS, ATG, ATS

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Specify source

Horse Rabbit Other

110

Specify other source:111

Anthracycline

yes no

112

Daunorubicin

yes no

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

116

Total dose:117 mg

Date started:118 __ __ __ __ - __ __- __ __

Idarubicin

yes no

119

Total dose:120 mg

Date started:121 __ __ __ __ - __ __- __ __

Rubidazone

yes no

122

Total dose:123 mg

Date started:124 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

125

Total dose:126 mg

Date started:127 __ __ __ __ - __ __- __ __

Specify other anthracycline:128

Bleomycin (BLM, Blenoxane)

yes no

129

Total dose:130 mg

Date started:131 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

135

Carboplatin

yes no

136

Total dose:137 mg

Date started:138 __ __ __ __ - __ __- __ __

Cisplatin (Platinol, CDDP)

yes no

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

145

(excluding anti-nausea medication)

Methylprednisolone (Solu-Medrol)

yes no

146

Total dose:147 mg

Date started:148 __ __ __ __ - __ __- __ __

Prednisone

yes no

149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Specify other corticosteroid:158

Cyclophosphamide (Cytoxan)

yes no

159

Total dose:160 mg

Date started:161 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

162

Total dose:163 mg

Date started:164 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

165

Total dose:166 mg

Date started:167 __ __ __ __ - __ __- __ __

Fludarabine

yes no

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Intrathecal therapy

yes no

177

Intrathecal cytarabine (IT Ara-C)

yes no

178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

184

Total dose:185 mg

Date started:186 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

187

Total dose:188 mg

Date started:189 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:190

Melphalan (L-Pam)

yes no

191

Total dose:192 mg

Date started:193 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

194

Mitoxantrone (Novantrone)

yes no

195

Total dose:196 mg

Date started:197 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

198

Radio labeled MAb

yes no

199

Total dose of radioactive component:200 mCi MBq

Date started:201 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

202

Ibritumomab tiuxetan (Zevalin)

yes no

203

Other radio labeled MAb

yes no

204

Specify other radio labeled MAb:205

Alemtuzumab (Campath)

yes no

206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

209

Total dose:210 mg

Date started:211 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

212

Total dose:213 mg

Date started:214 __ __ __ __ - __ __- __ __

Other MAb

yes no

215

Total dose:216 mg

Date started:217 __ __ __ __ - __ __- __ __

Specify other MAb:218

Nitrosourea

yes no

219

Carmustine (BCNU)

yes no

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Specify other nitrosourea:229

Paclitaxel (Taxol, Xyotax)

yes no

230

Total dose:231 mg

Date started:232 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Thiotepa

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Other drug

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Specify other drug:242

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

243

Busulfan

yes no

244

Carboplatin

yes no

245

Other drug

yes no

246

Specify other drug:247

Socioeconomic Information Questions: 248 - 264

Is the recipient an adult (18 years of age or older) or emancipated minor?

yes no

248

Specify the recipient’s marital status249

single, never married

married or living with a partner

separated

divorced

widowed

Unknown

Specify the category which best describes the recipient’s current occupation250
(If the recipient is not currently employed, check the box which best describes his/her last job.)

Professional, technical, or related occupation (e.g., teacher/professor, nurse/physician, lawyer, engineer)

Manager, administrator, or proprietor (e.g., sales manager, real estate agent, postmaster)

Clerical or related occupation (e.g., secretary, clerk, mail carrier)

Sales occupation (e.g., sales associate, demonstrator, agent, broker)

Service occupation (e.g., police officer, cook, hairdresser)

Skilled craft or related occupation (e.g., carpenter, repair technician, telephone line worker)

Equipment / vehicle operator or related occupation (e.g., driver, railroad brakeman, sewer worker)

Laborer (e.g., helper, longshoreman, warehouse worker)

Farmer (e.g., owner, manager, operator, tenant)

Member of the military

Homemaker

Student

Under school age

Not previously employed

Unknown

Other

Specify other occupation:251

What is the recipient’s current or most recent work status prior to illness?252

Full time

Part time, by choice and not due to illness

Part time, due to illness

Unemployed, by choice and not due to illness

Unemployed, due to illness

Medical disability

Retired

Unknown

What is the highest educational grade the recipient completed?253

No primary education / under school age: No schooling (US Equivalent: Less than 1st Grade Education)

Less than primary or elementary education: Some formal schooling, but less than a complete primary or elementary education (US Equivalent: More than 1st grade
education, but less than 6th grade education)

Primary or elementary education: Beginning at age 5-7 and continuing for about 4-6 years (US Equivalent: Starts with 1st grade and ends with 6th grade)

Lower secondary education: Beginning at about age 11-12 and continuing for about 2-3 years (US Equivalent: Starts with 7th grade and typically ends with 9th grade)

Upper secondary education: Beginning at about age 15-16 and continuing for about 3 years (US Equivalent: Starts with 10th grade and ends with 12th grade)

Post-secondary, non-tertiary education: Programs lasting 6 months - 2 years (US Equivalent: Vocational programs of study)

Tertiary education, Type A: Programs that provide education that is largely theoretical, lasting 3-4 years (US Equivalent: Includes university programs that last 4 years and
lead to the award of a bachelor's degree, and university programs that lead to a master's degree)

Tertiary education, Type B: Programs that focus on practical, technical or occupational skills with a minimum duration of 2 years of full-time enrollment (US Equivalent:
Programs typically offered at community colleges that lead to an associate's degree)

Advanced research qualification: Programs that lead to the award of an advanced post-graduate degree, such as a Ph.D. (US Equivalent: Programs devoted to advanced
study and original research)

Is the recipient currently in school, or was enrolled prior to illness?

yes no Unknown

254

Is the recipient covered by health insurance?

yes no

255

Government-sponsored Medicaid

yes no

256

(U.S.)

Government-sponsored Medicare

yes no

257

(U.S.)

Government-sponsored National Health Insurance

yes no

258

(non U.S.)

Government­sponsored Veteran’s Affairs / military

yes no

259

Private health insurance (premium paid by individual) or group health insurance

yes no

260

Employer-sponsored disability insurance

yes no

261

Other

yes no

262

Specify other health insurance:263

Specify the recipient’s combined household gross annual income264
(Include earnings by all family members living in the household, before taxes.) (For U.S. residents only)

Less than $20,000

$20,000–$39,999

$40,000–$59,999

$60,000–$79,999

$80,000–$99,999

$100,000 and over

Recipient declines to provide this information

Unknown

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Testing for evidence of prior viral exposure/infection

Specify radiation field:

Specify radio labeled MAb:

Specify drugs:

Specify type of health insurance:

Center: CRID: 

Form 2000 R4.0: Recipient Baseline Data

CIBMTR Form 2000 revision 4.0 last updated Monday, August 14, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 4 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Recipient ID:

Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Recipient Demographics Questions: 1 - 5

Country of primary residence1

Specify:2

State of residence of recipient:3

(for residents of USA)

Race (1) Questions: 4 - 5

Race4

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

Race detail5

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 6 - 14

Specify blood type

A B AB O

6

(For allogeneic HCTs only)

Specify Rh factor

Positive Negative

7

(For allogeneic HCTs only)

Does the recipient have a history of smoking cigarettes?

yes no Unknown

8

Has the recipient smoked cigarettes within the past year?

yes no Unknown

9

Has the recipient smoked cigarettes prior to but not during the past year?

yes no Unknown

10

Number of years

Known Unknown

11

Number of years:12

Average number of packs per day

Known Unknown

13

Average number of packs per day:14

Organ Function Prior to the Preparative Regimen (Conditioning) Questions: 15 - 38

AST (SGOT)

Known Unknown

15

16 U/L µkat/L

Date sample collected:17 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:18 U/L µkat/L

Total serum bilirubin

Known Unknown

19

20 mg/dL µmol/L

Date sample collected:21 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:22 mg/dL µmol/L

LDH

Known Unknown

23

24 U/L µkat/L

Date sample collected:25 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:26 U/L µkat/L

Serum creatinine

Known Unknown

27

28 mg/dL mmol/L µmol/L

Date sample collected:29 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:30 mg/dL mmol/L µmol/L

Total serum ferritin

Known Unknown

31

32 ng/mL (µg/L)

Date sample collected:33 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:34 ng/mL (µg/L)

Serum albumin

Known Unknown

35

36 g/dL g/L

Date sample collected:37 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:38 g/dL g/L

Hematologic Findings Prior to the Preparative Regimen (Conditioning) Questions: 39 - 54

Date CBC tested:39 __ __ __ __ - __ __- __ __

WBC

Known Unknown

40

41 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

42

43 %

Lymphocytes

Known Unknown

44

45 %

Hemoglobin

Known Unknown

46

47 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

48

Hematocrit

Known Unknown

49

50 %

Was RBC transfused < 30 days before date of test?

yes no

51

Platelets

Known Unknown

52

53 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused < 7 days before date of test?

yes no

54

Infection Questions: 55 - 75

Did the recipient have a history of clinically significant fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

55

Did the recipient have more than one fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

56

Fungal Infection (1) Questions: 57 - 63

Date of onset:57 __ __ __ __ - __ __- __ __

Select organism from list below58

210 Aspergillus, NOS

211 Aspergillus flavus

212 Aspergillus fumigatus

213 Aspergillus niger

215 Aspergillus terreus

214 Aspergillus ustus

270 Blastomyces (dermatitidis)

201 Candida albicans

208 Candida non-albicans

271 Coccidioides (all species)

222 Cryptococcus gattii

221 Cryptococcus neoformans

230 Fusarium (all species)

261 Histoplasma (capsulatum)

241 Mucorales (all species)

260 Pneumocystis (PCP / PJP)

242 Rhizopus (all species)

272 Scedosporium (all species)

240 Zygomycetes, NOS

503 Suspected fungal infection

Specify organism:59

Select site(s) from list below60

Select site(s) from list below61

Select site(s) from list below62

Was this fungal infection active within 2 weeks prior to the preparative regimen?

yes no

63

HTLV1 antibody

Reactive Non-reactive Inconclusive Not done

64

Cytomegalovirus antibody

Reactive Non-reactive Inconclusive Not done

65

Anti-EBV (Epstein-Barr virus antibody)

Positive Negative Inconclusive Not done

66

Hepatitis B surface antibody

Reactive Non-reactive Inconclusive Not done

67

Anti HBc: (hepatitis B core antibody)68

Reactive -For hepatitis tests that have a reactive result, also complete HEP form. 

Non-reactive

Not done

HBsAg: (hepatitis B surface antigen)69

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Not done

Hepatitis B — DNA70

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Anti-HCV: (hepatitis C antibody)71

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis C – NAT72

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis A antibody

Reactive Non-reactive Inconclusive Not done

73

HIV antibody

Positive Negative Inconclusive Not done Not reported

74

HIV – NAT

Positive Negative Inconclusive Not done Not reported

75

Pre-HCT Preparative Regimen (Conditioning) Questions: 76 - 247

Was a pre-HCT preparative regimen given?

yes no

76

Specify protocol intent77

(check only one) (Allogeneic HCTs only)

all agents given as outpatient

some, but not all, agents given as inpatient

all agents given as inpatient

Date pre-HCT preparative regimen
(irradiation or drugs) began:

78 __ __ __ __ - __ __- __ __

Use the earliest date from questions 82 (radiation) or 109-176 and 193-241 (systemic therapy).  Additional radiation and/or intrathecal
chemotherapy start dates may be prior to the date the preparative regimen began.  

Was irradiation performed as part of the pre-HCT preparative regimen?

yes no

79

What was the radiation field?80

total body

total body by tomotherapy

total lymphoid or nodal regions

thoracoabdominal region

Total dose:81

(dose per fraction x total number of fractions)

Gy cGy

Date started:82 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

83

Dose per fraction:84 Gy cGy

Number of days:85

(include "rest" days)

Total number of fractions:86

Was additional radiation given to other sites within 14 days of the pre-HCT preparative regimen?

yes no

87

CNS

yes no

88

Total dose:89 Gy cGy

Date started:90 __ __ __ __ - __ __- __ __

Gonadal

yes no

91

Total dose:92 Gy cGy

Date started:93 __ __ __ __ - __ __- __ __

Splenic

yes no

94

Total dose:95 Gy cGy

Date started:96 __ __ __ __ - __ __- __ __

Site of residual tumor

yes no

97

Total dose:98 Gy cGy

Date started:99 __ __ __ __ - __ __- __ __

Specify site:100

Other site

yes no

101

Total dose:102 Gy cGy

Date started:103 __ __ __ __ - __ __- __ __

Specify other site:104

Were drugs given for pre-HCT preparative regimen?

yes no

105

Dosing body weight used for pre-HCT preparative regimen (adjusted body weight):106 pounds kilograms

ALG, ALS, ATG, ATS

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Specify source

Horse Rabbit Other

110

Specify other source:111

Anthracycline

yes no

112

Daunorubicin

yes no

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

116

Total dose:117 mg

Date started:118 __ __ __ __ - __ __- __ __

Idarubicin

yes no

119

Total dose:120 mg

Date started:121 __ __ __ __ - __ __- __ __

Rubidazone

yes no

122

Total dose:123 mg

Date started:124 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

125

Total dose:126 mg

Date started:127 __ __ __ __ - __ __- __ __

Specify other anthracycline:128

Bleomycin (BLM, Blenoxane)

yes no

129

Total dose:130 mg

Date started:131 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

135

Carboplatin

yes no

136

Total dose:137 mg

Date started:138 __ __ __ __ - __ __- __ __

Cisplatin (Platinol, CDDP)

yes no

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

145

(excluding anti-nausea medication)

Methylprednisolone (Solu-Medrol)

yes no

146

Total dose:147 mg

Date started:148 __ __ __ __ - __ __- __ __

Prednisone

yes no

149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Specify other corticosteroid:158

Cyclophosphamide (Cytoxan)

yes no

159

Total dose:160 mg

Date started:161 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

162

Total dose:163 mg

Date started:164 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

165

Total dose:166 mg

Date started:167 __ __ __ __ - __ __- __ __

Fludarabine

yes no

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Intrathecal therapy

yes no

177

Intrathecal cytarabine (IT Ara-C)

yes no

178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

184

Total dose:185 mg

Date started:186 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

187

Total dose:188 mg

Date started:189 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:190

Melphalan (L-Pam)

yes no

191

Total dose:192 mg

Date started:193 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

194

Mitoxantrone (Novantrone)

yes no

195

Total dose:196 mg

Date started:197 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

198

Radio labeled MAb

yes no

199

Total dose of radioactive component:200 mCi MBq

Date started:201 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

202

Ibritumomab tiuxetan (Zevalin)

yes no

203

Other radio labeled MAb

yes no

204

Specify other radio labeled MAb:205

Alemtuzumab (Campath)

yes no

206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

209

Total dose:210 mg

Date started:211 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

212

Total dose:213 mg

Date started:214 __ __ __ __ - __ __- __ __

Other MAb

yes no

215

Total dose:216 mg

Date started:217 __ __ __ __ - __ __- __ __

Specify other MAb:218

Nitrosourea

yes no

219

Carmustine (BCNU)

yes no

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Specify other nitrosourea:229

Paclitaxel (Taxol, Xyotax)

yes no

230

Total dose:231 mg

Date started:232 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Thiotepa

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Other drug

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Specify other drug:242

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

243

Busulfan

yes no

244

Carboplatin

yes no

245

Other drug

yes no

246

Specify other drug:247

Socioeconomic Information Questions: 248 - 264

Is the recipient an adult (18 years of age or older) or emancipated minor?

yes no

248

Specify the recipient’s marital status249

single, never married

married or living with a partner

separated

divorced

widowed

Unknown

Specify the category which best describes the recipient’s current occupation250
(If the recipient is not currently employed, check the box which best describes his/her last job.)

Professional, technical, or related occupation (e.g., teacher/professor, nurse/physician, lawyer, engineer)

Manager, administrator, or proprietor (e.g., sales manager, real estate agent, postmaster)

Clerical or related occupation (e.g., secretary, clerk, mail carrier)

Sales occupation (e.g., sales associate, demonstrator, agent, broker)

Service occupation (e.g., police officer, cook, hairdresser)

Skilled craft or related occupation (e.g., carpenter, repair technician, telephone line worker)

Equipment / vehicle operator or related occupation (e.g., driver, railroad brakeman, sewer worker)

Laborer (e.g., helper, longshoreman, warehouse worker)

Farmer (e.g., owner, manager, operator, tenant)

Member of the military

Homemaker

Student

Under school age

Not previously employed

Unknown

Other

Specify other occupation:251

What is the recipient’s current or most recent work status prior to illness?252

Full time

Part time, by choice and not due to illness

Part time, due to illness

Unemployed, by choice and not due to illness

Unemployed, due to illness

Medical disability

Retired

Unknown

What is the highest educational grade the recipient completed?253

No primary education / under school age: No schooling (US Equivalent: Less than 1st Grade Education)

Less than primary or elementary education: Some formal schooling, but less than a complete primary or elementary education (US Equivalent: More than 1st grade
education, but less than 6th grade education)

Primary or elementary education: Beginning at age 5-7 and continuing for about 4-6 years (US Equivalent: Starts with 1st grade and ends with 6th grade)

Lower secondary education: Beginning at about age 11-12 and continuing for about 2-3 years (US Equivalent: Starts with 7th grade and typically ends with 9th grade)

Upper secondary education: Beginning at about age 15-16 and continuing for about 3 years (US Equivalent: Starts with 10th grade and ends with 12th grade)

Post-secondary, non-tertiary education: Programs lasting 6 months - 2 years (US Equivalent: Vocational programs of study)

Tertiary education, Type A: Programs that provide education that is largely theoretical, lasting 3-4 years (US Equivalent: Includes university programs that last 4 years and
lead to the award of a bachelor's degree, and university programs that lead to a master's degree)

Tertiary education, Type B: Programs that focus on practical, technical or occupational skills with a minimum duration of 2 years of full-time enrollment (US Equivalent:
Programs typically offered at community colleges that lead to an associate's degree)

Advanced research qualification: Programs that lead to the award of an advanced post-graduate degree, such as a Ph.D. (US Equivalent: Programs devoted to advanced
study and original research)

Is the recipient currently in school, or was enrolled prior to illness?

yes no Unknown

254

Is the recipient covered by health insurance?

yes no

255

Government-sponsored Medicaid

yes no

256

(U.S.)

Government-sponsored Medicare

yes no

257

(U.S.)

Government-sponsored National Health Insurance

yes no

258

(non U.S.)

Government­sponsored Veteran’s Affairs / military

yes no

259

Private health insurance (premium paid by individual) or group health insurance

yes no

260

Employer-sponsored disability insurance

yes no

261

Other

yes no

262

Specify other health insurance:263

Specify the recipient’s combined household gross annual income264
(Include earnings by all family members living in the household, before taxes.) (For U.S. residents only)

Less than $20,000

$20,000–$39,999

$40,000–$59,999

$60,000–$79,999

$80,000–$99,999

$100,000 and over

Recipient declines to provide this information

Unknown

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Testing for evidence of prior viral exposure/infection

Specify radiation field:

Specify radio labeled MAb:

Specify drugs:

Specify type of health insurance:

Center: CRID: 

Form 2000 R4.0: Recipient Baseline Data

CIBMTR Form 2000 revision 4.0 last updated Monday, August 14, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 5 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Recipient ID:

Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Recipient Demographics Questions: 1 - 5

Country of primary residence1

Specify:2

State of residence of recipient:3

(for residents of USA)

Race (1) Questions: 4 - 5

Race4

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

Race detail5

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 6 - 14

Specify blood type

A B AB O

6

(For allogeneic HCTs only)

Specify Rh factor

Positive Negative

7

(For allogeneic HCTs only)

Does the recipient have a history of smoking cigarettes?

yes no Unknown

8

Has the recipient smoked cigarettes within the past year?

yes no Unknown

9

Has the recipient smoked cigarettes prior to but not during the past year?

yes no Unknown

10

Number of years

Known Unknown

11

Number of years:12

Average number of packs per day

Known Unknown

13

Average number of packs per day:14

Organ Function Prior to the Preparative Regimen (Conditioning) Questions: 15 - 38

AST (SGOT)

Known Unknown

15

16 U/L µkat/L

Date sample collected:17 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:18 U/L µkat/L

Total serum bilirubin

Known Unknown

19

20 mg/dL µmol/L

Date sample collected:21 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:22 mg/dL µmol/L

LDH

Known Unknown

23

24 U/L µkat/L

Date sample collected:25 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:26 U/L µkat/L

Serum creatinine

Known Unknown

27

28 mg/dL mmol/L µmol/L

Date sample collected:29 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:30 mg/dL mmol/L µmol/L

Total serum ferritin

Known Unknown

31

32 ng/mL (µg/L)

Date sample collected:33 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:34 ng/mL (µg/L)

Serum albumin

Known Unknown

35

36 g/dL g/L

Date sample collected:37 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:38 g/dL g/L

Hematologic Findings Prior to the Preparative Regimen (Conditioning) Questions: 39 - 54

Date CBC tested:39 __ __ __ __ - __ __- __ __

WBC

Known Unknown

40

41 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

42

43 %

Lymphocytes

Known Unknown

44

45 %

Hemoglobin

Known Unknown

46

47 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

48

Hematocrit

Known Unknown

49

50 %

Was RBC transfused < 30 days before date of test?

yes no

51

Platelets

Known Unknown

52

53 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused < 7 days before date of test?

yes no

54

Infection Questions: 55 - 75

Did the recipient have a history of clinically significant fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

55

Did the recipient have more than one fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

56

Fungal Infection (1) Questions: 57 - 63

Date of onset:57 __ __ __ __ - __ __- __ __

Select organism from list below58

210 Aspergillus, NOS

211 Aspergillus flavus

212 Aspergillus fumigatus

213 Aspergillus niger

215 Aspergillus terreus

214 Aspergillus ustus

270 Blastomyces (dermatitidis)

201 Candida albicans

208 Candida non-albicans

271 Coccidioides (all species)

222 Cryptococcus gattii

221 Cryptococcus neoformans

230 Fusarium (all species)

261 Histoplasma (capsulatum)

241 Mucorales (all species)

260 Pneumocystis (PCP / PJP)

242 Rhizopus (all species)

272 Scedosporium (all species)

240 Zygomycetes, NOS

503 Suspected fungal infection

Specify organism:59

Select site(s) from list below60

Select site(s) from list below61

Select site(s) from list below62

Was this fungal infection active within 2 weeks prior to the preparative regimen?

yes no

63

HTLV1 antibody

Reactive Non-reactive Inconclusive Not done

64

Cytomegalovirus antibody

Reactive Non-reactive Inconclusive Not done

65

Anti-EBV (Epstein-Barr virus antibody)

Positive Negative Inconclusive Not done

66

Hepatitis B surface antibody

Reactive Non-reactive Inconclusive Not done

67

Anti HBc: (hepatitis B core antibody)68

Reactive -For hepatitis tests that have a reactive result, also complete HEP form. 

Non-reactive

Not done

HBsAg: (hepatitis B surface antigen)69

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Not done

Hepatitis B — DNA70

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Anti-HCV: (hepatitis C antibody)71

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis C – NAT72

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis A antibody

Reactive Non-reactive Inconclusive Not done

73

HIV antibody

Positive Negative Inconclusive Not done Not reported

74

HIV – NAT

Positive Negative Inconclusive Not done Not reported

75

Pre-HCT Preparative Regimen (Conditioning) Questions: 76 - 247

Was a pre-HCT preparative regimen given?

yes no

76

Specify protocol intent77

(check only one) (Allogeneic HCTs only)

all agents given as outpatient

some, but not all, agents given as inpatient

all agents given as inpatient

Date pre-HCT preparative regimen
(irradiation or drugs) began:

78 __ __ __ __ - __ __- __ __

Use the earliest date from questions 82 (radiation) or 109-176 and 193-241 (systemic therapy).  Additional radiation and/or intrathecal
chemotherapy start dates may be prior to the date the preparative regimen began.  

Was irradiation performed as part of the pre-HCT preparative regimen?

yes no

79

What was the radiation field?80

total body

total body by tomotherapy

total lymphoid or nodal regions

thoracoabdominal region

Total dose:81

(dose per fraction x total number of fractions)

Gy cGy

Date started:82 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

83

Dose per fraction:84 Gy cGy

Number of days:85

(include "rest" days)

Total number of fractions:86

Was additional radiation given to other sites within 14 days of the pre-HCT preparative regimen?

yes no

87

CNS

yes no

88

Total dose:89 Gy cGy

Date started:90 __ __ __ __ - __ __- __ __

Gonadal

yes no

91

Total dose:92 Gy cGy

Date started:93 __ __ __ __ - __ __- __ __

Splenic

yes no

94

Total dose:95 Gy cGy

Date started:96 __ __ __ __ - __ __- __ __

Site of residual tumor

yes no

97

Total dose:98 Gy cGy

Date started:99 __ __ __ __ - __ __- __ __

Specify site:100

Other site

yes no

101

Total dose:102 Gy cGy

Date started:103 __ __ __ __ - __ __- __ __

Specify other site:104

Were drugs given for pre-HCT preparative regimen?

yes no

105

Dosing body weight used for pre-HCT preparative regimen (adjusted body weight):106 pounds kilograms

ALG, ALS, ATG, ATS

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Specify source

Horse Rabbit Other

110

Specify other source:111

Anthracycline

yes no

112

Daunorubicin

yes no

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

116

Total dose:117 mg

Date started:118 __ __ __ __ - __ __- __ __

Idarubicin

yes no

119

Total dose:120 mg

Date started:121 __ __ __ __ - __ __- __ __

Rubidazone

yes no

122

Total dose:123 mg

Date started:124 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

125

Total dose:126 mg

Date started:127 __ __ __ __ - __ __- __ __

Specify other anthracycline:128

Bleomycin (BLM, Blenoxane)

yes no

129

Total dose:130 mg

Date started:131 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

135

Carboplatin

yes no

136

Total dose:137 mg

Date started:138 __ __ __ __ - __ __- __ __

Cisplatin (Platinol, CDDP)

yes no

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

145

(excluding anti-nausea medication)

Methylprednisolone (Solu-Medrol)

yes no

146

Total dose:147 mg

Date started:148 __ __ __ __ - __ __- __ __

Prednisone

yes no

149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Specify other corticosteroid:158

Cyclophosphamide (Cytoxan)

yes no

159

Total dose:160 mg

Date started:161 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

162

Total dose:163 mg

Date started:164 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

165

Total dose:166 mg

Date started:167 __ __ __ __ - __ __- __ __

Fludarabine

yes no

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Intrathecal therapy

yes no

177

Intrathecal cytarabine (IT Ara-C)

yes no

178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

184

Total dose:185 mg

Date started:186 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

187

Total dose:188 mg

Date started:189 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:190

Melphalan (L-Pam)

yes no

191

Total dose:192 mg

Date started:193 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

194

Mitoxantrone (Novantrone)

yes no

195

Total dose:196 mg

Date started:197 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

198

Radio labeled MAb

yes no

199

Total dose of radioactive component:200 mCi MBq

Date started:201 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

202

Ibritumomab tiuxetan (Zevalin)

yes no

203

Other radio labeled MAb

yes no

204

Specify other radio labeled MAb:205

Alemtuzumab (Campath)

yes no

206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

209

Total dose:210 mg

Date started:211 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

212

Total dose:213 mg

Date started:214 __ __ __ __ - __ __- __ __

Other MAb

yes no

215

Total dose:216 mg

Date started:217 __ __ __ __ - __ __- __ __

Specify other MAb:218

Nitrosourea

yes no

219

Carmustine (BCNU)

yes no

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Specify other nitrosourea:229

Paclitaxel (Taxol, Xyotax)

yes no

230

Total dose:231 mg

Date started:232 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Thiotepa

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Other drug

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Specify other drug:242

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

243

Busulfan

yes no

244

Carboplatin

yes no

245

Other drug

yes no

246

Specify other drug:247

Socioeconomic Information Questions: 248 - 264

Is the recipient an adult (18 years of age or older) or emancipated minor?

yes no

248

Specify the recipient’s marital status249

single, never married

married or living with a partner

separated

divorced

widowed

Unknown

Specify the category which best describes the recipient’s current occupation250
(If the recipient is not currently employed, check the box which best describes his/her last job.)

Professional, technical, or related occupation (e.g., teacher/professor, nurse/physician, lawyer, engineer)

Manager, administrator, or proprietor (e.g., sales manager, real estate agent, postmaster)

Clerical or related occupation (e.g., secretary, clerk, mail carrier)

Sales occupation (e.g., sales associate, demonstrator, agent, broker)

Service occupation (e.g., police officer, cook, hairdresser)

Skilled craft or related occupation (e.g., carpenter, repair technician, telephone line worker)

Equipment / vehicle operator or related occupation (e.g., driver, railroad brakeman, sewer worker)

Laborer (e.g., helper, longshoreman, warehouse worker)

Farmer (e.g., owner, manager, operator, tenant)

Member of the military

Homemaker

Student

Under school age

Not previously employed

Unknown

Other

Specify other occupation:251

What is the recipient’s current or most recent work status prior to illness?252

Full time

Part time, by choice and not due to illness

Part time, due to illness

Unemployed, by choice and not due to illness

Unemployed, due to illness

Medical disability

Retired

Unknown

What is the highest educational grade the recipient completed?253

No primary education / under school age: No schooling (US Equivalent: Less than 1st Grade Education)

Less than primary or elementary education: Some formal schooling, but less than a complete primary or elementary education (US Equivalent: More than 1st grade
education, but less than 6th grade education)

Primary or elementary education: Beginning at age 5-7 and continuing for about 4-6 years (US Equivalent: Starts with 1st grade and ends with 6th grade)

Lower secondary education: Beginning at about age 11-12 and continuing for about 2-3 years (US Equivalent: Starts with 7th grade and typically ends with 9th grade)

Upper secondary education: Beginning at about age 15-16 and continuing for about 3 years (US Equivalent: Starts with 10th grade and ends with 12th grade)

Post-secondary, non-tertiary education: Programs lasting 6 months - 2 years (US Equivalent: Vocational programs of study)

Tertiary education, Type A: Programs that provide education that is largely theoretical, lasting 3-4 years (US Equivalent: Includes university programs that last 4 years and
lead to the award of a bachelor's degree, and university programs that lead to a master's degree)

Tertiary education, Type B: Programs that focus on practical, technical or occupational skills with a minimum duration of 2 years of full-time enrollment (US Equivalent:
Programs typically offered at community colleges that lead to an associate's degree)

Advanced research qualification: Programs that lead to the award of an advanced post-graduate degree, such as a Ph.D. (US Equivalent: Programs devoted to advanced
study and original research)

Is the recipient currently in school, or was enrolled prior to illness?

yes no Unknown

254

Is the recipient covered by health insurance?

yes no

255

Government-sponsored Medicaid

yes no

256

(U.S.)

Government-sponsored Medicare

yes no

257

(U.S.)

Government-sponsored National Health Insurance

yes no

258

(non U.S.)

Government­sponsored Veteran’s Affairs / military

yes no

259

Private health insurance (premium paid by individual) or group health insurance

yes no

260

Employer-sponsored disability insurance

yes no

261

Other

yes no

262

Specify other health insurance:263

Specify the recipient’s combined household gross annual income264
(Include earnings by all family members living in the household, before taxes.) (For U.S. residents only)

Less than $20,000

$20,000–$39,999

$40,000–$59,999

$60,000–$79,999

$80,000–$99,999

$100,000 and over

Recipient declines to provide this information

Unknown

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Testing for evidence of prior viral exposure/infection

Specify radiation field:

Specify radio labeled MAb:

Specify drugs:

Specify type of health insurance:

Center: CRID: 

Form 2000 R4.0: Recipient Baseline Data

CIBMTR Form 2000 revision 4.0 last updated Monday, August 14, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 6 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Recipient ID:

Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Recipient Demographics Questions: 1 - 5

Country of primary residence1

Specify:2

State of residence of recipient:3

(for residents of USA)

Race (1) Questions: 4 - 5

Race4

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

Race detail5

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 6 - 14

Specify blood type

A B AB O

6

(For allogeneic HCTs only)

Specify Rh factor

Positive Negative

7

(For allogeneic HCTs only)

Does the recipient have a history of smoking cigarettes?

yes no Unknown

8

Has the recipient smoked cigarettes within the past year?

yes no Unknown

9

Has the recipient smoked cigarettes prior to but not during the past year?

yes no Unknown

10

Number of years

Known Unknown

11

Number of years:12

Average number of packs per day

Known Unknown

13

Average number of packs per day:14

Organ Function Prior to the Preparative Regimen (Conditioning) Questions: 15 - 38

AST (SGOT)

Known Unknown

15

16 U/L µkat/L

Date sample collected:17 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:18 U/L µkat/L

Total serum bilirubin

Known Unknown

19

20 mg/dL µmol/L

Date sample collected:21 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:22 mg/dL µmol/L

LDH

Known Unknown

23

24 U/L µkat/L

Date sample collected:25 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:26 U/L µkat/L

Serum creatinine

Known Unknown

27

28 mg/dL mmol/L µmol/L

Date sample collected:29 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:30 mg/dL mmol/L µmol/L

Total serum ferritin

Known Unknown

31

32 ng/mL (µg/L)

Date sample collected:33 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:34 ng/mL (µg/L)

Serum albumin

Known Unknown

35

36 g/dL g/L

Date sample collected:37 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:38 g/dL g/L

Hematologic Findings Prior to the Preparative Regimen (Conditioning) Questions: 39 - 54

Date CBC tested:39 __ __ __ __ - __ __- __ __

WBC

Known Unknown

40

41 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

42

43 %

Lymphocytes

Known Unknown

44

45 %

Hemoglobin

Known Unknown

46

47 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

48

Hematocrit

Known Unknown

49

50 %

Was RBC transfused < 30 days before date of test?

yes no

51

Platelets

Known Unknown

52

53 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused < 7 days before date of test?

yes no

54

Infection Questions: 55 - 75

Did the recipient have a history of clinically significant fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

55

Did the recipient have more than one fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

56

Fungal Infection (1) Questions: 57 - 63

Date of onset:57 __ __ __ __ - __ __- __ __

Select organism from list below58

210 Aspergillus, NOS

211 Aspergillus flavus

212 Aspergillus fumigatus

213 Aspergillus niger

215 Aspergillus terreus

214 Aspergillus ustus

270 Blastomyces (dermatitidis)

201 Candida albicans

208 Candida non-albicans

271 Coccidioides (all species)

222 Cryptococcus gattii

221 Cryptococcus neoformans

230 Fusarium (all species)

261 Histoplasma (capsulatum)

241 Mucorales (all species)

260 Pneumocystis (PCP / PJP)

242 Rhizopus (all species)

272 Scedosporium (all species)

240 Zygomycetes, NOS

503 Suspected fungal infection

Specify organism:59

Select site(s) from list below60

Select site(s) from list below61

Select site(s) from list below62

Was this fungal infection active within 2 weeks prior to the preparative regimen?

yes no

63

HTLV1 antibody

Reactive Non-reactive Inconclusive Not done

64

Cytomegalovirus antibody

Reactive Non-reactive Inconclusive Not done

65

Anti-EBV (Epstein-Barr virus antibody)

Positive Negative Inconclusive Not done

66

Hepatitis B surface antibody

Reactive Non-reactive Inconclusive Not done

67

Anti HBc: (hepatitis B core antibody)68

Reactive -For hepatitis tests that have a reactive result, also complete HEP form. 

Non-reactive

Not done

HBsAg: (hepatitis B surface antigen)69

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Not done

Hepatitis B — DNA70

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Anti-HCV: (hepatitis C antibody)71

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis C – NAT72

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis A antibody

Reactive Non-reactive Inconclusive Not done

73

HIV antibody

Positive Negative Inconclusive Not done Not reported

74

HIV – NAT

Positive Negative Inconclusive Not done Not reported

75

Pre-HCT Preparative Regimen (Conditioning) Questions: 76 - 247

Was a pre-HCT preparative regimen given?

yes no

76

Specify protocol intent77

(check only one) (Allogeneic HCTs only)

all agents given as outpatient

some, but not all, agents given as inpatient

all agents given as inpatient

Date pre-HCT preparative regimen
(irradiation or drugs) began:

78 __ __ __ __ - __ __- __ __

Use the earliest date from questions 82 (radiation) or 109-176 and 193-241 (systemic therapy).  Additional radiation and/or intrathecal
chemotherapy start dates may be prior to the date the preparative regimen began.  

Was irradiation performed as part of the pre-HCT preparative regimen?

yes no

79

What was the radiation field?80

total body

total body by tomotherapy

total lymphoid or nodal regions

thoracoabdominal region

Total dose:81

(dose per fraction x total number of fractions)

Gy cGy

Date started:82 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

83

Dose per fraction:84 Gy cGy

Number of days:85

(include "rest" days)

Total number of fractions:86

Was additional radiation given to other sites within 14 days of the pre-HCT preparative regimen?

yes no

87

CNS

yes no

88

Total dose:89 Gy cGy

Date started:90 __ __ __ __ - __ __- __ __

Gonadal

yes no

91

Total dose:92 Gy cGy

Date started:93 __ __ __ __ - __ __- __ __

Splenic

yes no

94

Total dose:95 Gy cGy

Date started:96 __ __ __ __ - __ __- __ __

Site of residual tumor

yes no

97

Total dose:98 Gy cGy

Date started:99 __ __ __ __ - __ __- __ __

Specify site:100

Other site

yes no

101

Total dose:102 Gy cGy

Date started:103 __ __ __ __ - __ __- __ __

Specify other site:104

Were drugs given for pre-HCT preparative regimen?

yes no

105

Dosing body weight used for pre-HCT preparative regimen (adjusted body weight):106 pounds kilograms

ALG, ALS, ATG, ATS

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Specify source

Horse Rabbit Other

110

Specify other source:111

Anthracycline

yes no

112

Daunorubicin

yes no

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

116

Total dose:117 mg

Date started:118 __ __ __ __ - __ __- __ __

Idarubicin

yes no

119

Total dose:120 mg

Date started:121 __ __ __ __ - __ __- __ __

Rubidazone

yes no

122

Total dose:123 mg

Date started:124 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

125

Total dose:126 mg

Date started:127 __ __ __ __ - __ __- __ __

Specify other anthracycline:128

Bleomycin (BLM, Blenoxane)

yes no

129

Total dose:130 mg

Date started:131 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

135

Carboplatin

yes no

136

Total dose:137 mg

Date started:138 __ __ __ __ - __ __- __ __

Cisplatin (Platinol, CDDP)

yes no

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

145

(excluding anti-nausea medication)

Methylprednisolone (Solu-Medrol)

yes no

146

Total dose:147 mg

Date started:148 __ __ __ __ - __ __- __ __

Prednisone

yes no

149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Specify other corticosteroid:158

Cyclophosphamide (Cytoxan)

yes no

159

Total dose:160 mg

Date started:161 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

162

Total dose:163 mg

Date started:164 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

165

Total dose:166 mg

Date started:167 __ __ __ __ - __ __- __ __

Fludarabine

yes no

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Intrathecal therapy

yes no

177

Intrathecal cytarabine (IT Ara-C)

yes no

178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

184

Total dose:185 mg

Date started:186 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

187

Total dose:188 mg

Date started:189 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:190

Melphalan (L-Pam)

yes no

191

Total dose:192 mg

Date started:193 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

194

Mitoxantrone (Novantrone)

yes no

195

Total dose:196 mg

Date started:197 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

198

Radio labeled MAb

yes no

199

Total dose of radioactive component:200 mCi MBq

Date started:201 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

202

Ibritumomab tiuxetan (Zevalin)

yes no

203

Other radio labeled MAb

yes no

204

Specify other radio labeled MAb:205

Alemtuzumab (Campath)

yes no

206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

209

Total dose:210 mg

Date started:211 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

212

Total dose:213 mg

Date started:214 __ __ __ __ - __ __- __ __

Other MAb

yes no

215

Total dose:216 mg

Date started:217 __ __ __ __ - __ __- __ __

Specify other MAb:218

Nitrosourea

yes no

219

Carmustine (BCNU)

yes no

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Specify other nitrosourea:229

Paclitaxel (Taxol, Xyotax)

yes no

230

Total dose:231 mg

Date started:232 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Thiotepa

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Other drug

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Specify other drug:242

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

243

Busulfan

yes no

244

Carboplatin

yes no

245

Other drug

yes no

246

Specify other drug:247

Socioeconomic Information Questions: 248 - 264

Is the recipient an adult (18 years of age or older) or emancipated minor?

yes no

248

Specify the recipient’s marital status249

single, never married

married or living with a partner

separated

divorced

widowed

Unknown

Specify the category which best describes the recipient’s current occupation250
(If the recipient is not currently employed, check the box which best describes his/her last job.)

Professional, technical, or related occupation (e.g., teacher/professor, nurse/physician, lawyer, engineer)

Manager, administrator, or proprietor (e.g., sales manager, real estate agent, postmaster)

Clerical or related occupation (e.g., secretary, clerk, mail carrier)

Sales occupation (e.g., sales associate, demonstrator, agent, broker)

Service occupation (e.g., police officer, cook, hairdresser)

Skilled craft or related occupation (e.g., carpenter, repair technician, telephone line worker)

Equipment / vehicle operator or related occupation (e.g., driver, railroad brakeman, sewer worker)

Laborer (e.g., helper, longshoreman, warehouse worker)

Farmer (e.g., owner, manager, operator, tenant)

Member of the military

Homemaker

Student

Under school age

Not previously employed

Unknown

Other

Specify other occupation:251

What is the recipient’s current or most recent work status prior to illness?252

Full time

Part time, by choice and not due to illness

Part time, due to illness

Unemployed, by choice and not due to illness

Unemployed, due to illness

Medical disability

Retired

Unknown

What is the highest educational grade the recipient completed?253

No primary education / under school age: No schooling (US Equivalent: Less than 1st Grade Education)

Less than primary or elementary education: Some formal schooling, but less than a complete primary or elementary education (US Equivalent: More than 1st grade
education, but less than 6th grade education)

Primary or elementary education: Beginning at age 5-7 and continuing for about 4-6 years (US Equivalent: Starts with 1st grade and ends with 6th grade)

Lower secondary education: Beginning at about age 11-12 and continuing for about 2-3 years (US Equivalent: Starts with 7th grade and typically ends with 9th grade)

Upper secondary education: Beginning at about age 15-16 and continuing for about 3 years (US Equivalent: Starts with 10th grade and ends with 12th grade)

Post-secondary, non-tertiary education: Programs lasting 6 months - 2 years (US Equivalent: Vocational programs of study)

Tertiary education, Type A: Programs that provide education that is largely theoretical, lasting 3-4 years (US Equivalent: Includes university programs that last 4 years and
lead to the award of a bachelor's degree, and university programs that lead to a master's degree)

Tertiary education, Type B: Programs that focus on practical, technical or occupational skills with a minimum duration of 2 years of full-time enrollment (US Equivalent:
Programs typically offered at community colleges that lead to an associate's degree)

Advanced research qualification: Programs that lead to the award of an advanced post-graduate degree, such as a Ph.D. (US Equivalent: Programs devoted to advanced
study and original research)

Is the recipient currently in school, or was enrolled prior to illness?

yes no Unknown

254

Is the recipient covered by health insurance?

yes no

255

Government-sponsored Medicaid

yes no

256

(U.S.)

Government-sponsored Medicare

yes no

257

(U.S.)

Government-sponsored National Health Insurance

yes no

258

(non U.S.)

Government­sponsored Veteran’s Affairs / military

yes no

259

Private health insurance (premium paid by individual) or group health insurance

yes no

260

Employer-sponsored disability insurance

yes no

261

Other

yes no

262

Specify other health insurance:263

Specify the recipient’s combined household gross annual income264
(Include earnings by all family members living in the household, before taxes.) (For U.S. residents only)

Less than $20,000

$20,000–$39,999

$40,000–$59,999

$60,000–$79,999

$80,000–$99,999

$100,000 and over

Recipient declines to provide this information

Unknown

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Testing for evidence of prior viral exposure/infection

Specify radiation field:

Specify radio labeled MAb:

Specify drugs:

Specify type of health insurance:

Center: CRID: 

Form 2000 R4.0: Recipient Baseline Data

CIBMTR Form 2000 revision 4.0 last updated Monday, August 14, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 7 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Recipient ID:

Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Recipient Demographics Questions: 1 - 5

Country of primary residence1

Specify:2

State of residence of recipient:3

(for residents of USA)

Race (1) Questions: 4 - 5

Race4

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

Race detail5

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 6 - 14

Specify blood type

A B AB O

6

(For allogeneic HCTs only)

Specify Rh factor

Positive Negative

7

(For allogeneic HCTs only)

Does the recipient have a history of smoking cigarettes?

yes no Unknown

8

Has the recipient smoked cigarettes within the past year?

yes no Unknown

9

Has the recipient smoked cigarettes prior to but not during the past year?

yes no Unknown

10

Number of years

Known Unknown

11

Number of years:12

Average number of packs per day

Known Unknown

13

Average number of packs per day:14

Organ Function Prior to the Preparative Regimen (Conditioning) Questions: 15 - 38

AST (SGOT)

Known Unknown

15

16 U/L µkat/L

Date sample collected:17 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:18 U/L µkat/L

Total serum bilirubin

Known Unknown

19

20 mg/dL µmol/L

Date sample collected:21 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:22 mg/dL µmol/L

LDH

Known Unknown

23

24 U/L µkat/L

Date sample collected:25 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:26 U/L µkat/L

Serum creatinine

Known Unknown

27

28 mg/dL mmol/L µmol/L

Date sample collected:29 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:30 mg/dL mmol/L µmol/L

Total serum ferritin

Known Unknown

31

32 ng/mL (µg/L)

Date sample collected:33 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:34 ng/mL (µg/L)

Serum albumin

Known Unknown

35

36 g/dL g/L

Date sample collected:37 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:38 g/dL g/L

Hematologic Findings Prior to the Preparative Regimen (Conditioning) Questions: 39 - 54

Date CBC tested:39 __ __ __ __ - __ __- __ __

WBC

Known Unknown

40

41 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

42

43 %

Lymphocytes

Known Unknown

44

45 %

Hemoglobin

Known Unknown

46

47 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

48

Hematocrit

Known Unknown

49

50 %

Was RBC transfused < 30 days before date of test?

yes no

51

Platelets

Known Unknown

52

53 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused < 7 days before date of test?

yes no

54

Infection Questions: 55 - 75

Did the recipient have a history of clinically significant fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

55

Did the recipient have more than one fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

56

Fungal Infection (1) Questions: 57 - 63

Date of onset:57 __ __ __ __ - __ __- __ __

Select organism from list below58

210 Aspergillus, NOS

211 Aspergillus flavus

212 Aspergillus fumigatus

213 Aspergillus niger

215 Aspergillus terreus

214 Aspergillus ustus

270 Blastomyces (dermatitidis)

201 Candida albicans

208 Candida non-albicans

271 Coccidioides (all species)

222 Cryptococcus gattii

221 Cryptococcus neoformans

230 Fusarium (all species)

261 Histoplasma (capsulatum)

241 Mucorales (all species)

260 Pneumocystis (PCP / PJP)

242 Rhizopus (all species)

272 Scedosporium (all species)

240 Zygomycetes, NOS

503 Suspected fungal infection

Specify organism:59

Select site(s) from list below60

Select site(s) from list below61

Select site(s) from list below62

Was this fungal infection active within 2 weeks prior to the preparative regimen?

yes no

63

HTLV1 antibody

Reactive Non-reactive Inconclusive Not done

64

Cytomegalovirus antibody

Reactive Non-reactive Inconclusive Not done

65

Anti-EBV (Epstein-Barr virus antibody)

Positive Negative Inconclusive Not done

66

Hepatitis B surface antibody

Reactive Non-reactive Inconclusive Not done

67

Anti HBc: (hepatitis B core antibody)68

Reactive -For hepatitis tests that have a reactive result, also complete HEP form. 

Non-reactive

Not done

HBsAg: (hepatitis B surface antigen)69

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Not done

Hepatitis B — DNA70

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Anti-HCV: (hepatitis C antibody)71

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis C – NAT72

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis A antibody

Reactive Non-reactive Inconclusive Not done

73

HIV antibody

Positive Negative Inconclusive Not done Not reported

74

HIV – NAT

Positive Negative Inconclusive Not done Not reported

75

Pre-HCT Preparative Regimen (Conditioning) Questions: 76 - 247

Was a pre-HCT preparative regimen given?

yes no

76

Specify protocol intent77

(check only one) (Allogeneic HCTs only)

all agents given as outpatient

some, but not all, agents given as inpatient

all agents given as inpatient

Date pre-HCT preparative regimen
(irradiation or drugs) began:

78 __ __ __ __ - __ __- __ __

Use the earliest date from questions 82 (radiation) or 109-176 and 193-241 (systemic therapy).  Additional radiation and/or intrathecal
chemotherapy start dates may be prior to the date the preparative regimen began.  

Was irradiation performed as part of the pre-HCT preparative regimen?

yes no

79

What was the radiation field?80

total body

total body by tomotherapy

total lymphoid or nodal regions

thoracoabdominal region

Total dose:81

(dose per fraction x total number of fractions)

Gy cGy

Date started:82 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

83

Dose per fraction:84 Gy cGy

Number of days:85

(include "rest" days)

Total number of fractions:86

Was additional radiation given to other sites within 14 days of the pre-HCT preparative regimen?

yes no

87

CNS

yes no

88

Total dose:89 Gy cGy

Date started:90 __ __ __ __ - __ __- __ __

Gonadal

yes no

91

Total dose:92 Gy cGy

Date started:93 __ __ __ __ - __ __- __ __

Splenic

yes no

94

Total dose:95 Gy cGy

Date started:96 __ __ __ __ - __ __- __ __

Site of residual tumor

yes no

97

Total dose:98 Gy cGy

Date started:99 __ __ __ __ - __ __- __ __

Specify site:100

Other site

yes no

101

Total dose:102 Gy cGy

Date started:103 __ __ __ __ - __ __- __ __

Specify other site:104

Were drugs given for pre-HCT preparative regimen?

yes no

105

Dosing body weight used for pre-HCT preparative regimen (adjusted body weight):106 pounds kilograms

ALG, ALS, ATG, ATS

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Specify source

Horse Rabbit Other

110

Specify other source:111

Anthracycline

yes no

112

Daunorubicin

yes no

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

116

Total dose:117 mg

Date started:118 __ __ __ __ - __ __- __ __

Idarubicin

yes no

119

Total dose:120 mg

Date started:121 __ __ __ __ - __ __- __ __

Rubidazone

yes no

122

Total dose:123 mg

Date started:124 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

125

Total dose:126 mg

Date started:127 __ __ __ __ - __ __- __ __

Specify other anthracycline:128

Bleomycin (BLM, Blenoxane)

yes no

129

Total dose:130 mg

Date started:131 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

135

Carboplatin

yes no

136

Total dose:137 mg

Date started:138 __ __ __ __ - __ __- __ __

Cisplatin (Platinol, CDDP)

yes no

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

145

(excluding anti-nausea medication)

Methylprednisolone (Solu-Medrol)

yes no

146

Total dose:147 mg

Date started:148 __ __ __ __ - __ __- __ __

Prednisone

yes no

149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Specify other corticosteroid:158

Cyclophosphamide (Cytoxan)

yes no

159

Total dose:160 mg

Date started:161 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

162

Total dose:163 mg

Date started:164 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

165

Total dose:166 mg

Date started:167 __ __ __ __ - __ __- __ __

Fludarabine

yes no

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Intrathecal therapy

yes no

177

Intrathecal cytarabine (IT Ara-C)

yes no

178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

184

Total dose:185 mg

Date started:186 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

187

Total dose:188 mg

Date started:189 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:190

Melphalan (L-Pam)

yes no

191

Total dose:192 mg

Date started:193 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

194

Mitoxantrone (Novantrone)

yes no

195

Total dose:196 mg

Date started:197 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

198

Radio labeled MAb

yes no

199

Total dose of radioactive component:200 mCi MBq

Date started:201 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

202

Ibritumomab tiuxetan (Zevalin)

yes no

203

Other radio labeled MAb

yes no

204

Specify other radio labeled MAb:205

Alemtuzumab (Campath)

yes no

206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

209

Total dose:210 mg

Date started:211 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

212

Total dose:213 mg

Date started:214 __ __ __ __ - __ __- __ __

Other MAb

yes no

215

Total dose:216 mg

Date started:217 __ __ __ __ - __ __- __ __

Specify other MAb:218

Nitrosourea

yes no

219

Carmustine (BCNU)

yes no

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Specify other nitrosourea:229

Paclitaxel (Taxol, Xyotax)

yes no

230

Total dose:231 mg

Date started:232 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Thiotepa

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Other drug

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Specify other drug:242

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

243

Busulfan

yes no

244

Carboplatin

yes no

245

Other drug

yes no

246

Specify other drug:247

Socioeconomic Information Questions: 248 - 264

Is the recipient an adult (18 years of age or older) or emancipated minor?

yes no

248

Specify the recipient’s marital status249

single, never married

married or living with a partner

separated

divorced

widowed

Unknown

Specify the category which best describes the recipient’s current occupation250
(If the recipient is not currently employed, check the box which best describes his/her last job.)

Professional, technical, or related occupation (e.g., teacher/professor, nurse/physician, lawyer, engineer)

Manager, administrator, or proprietor (e.g., sales manager, real estate agent, postmaster)

Clerical or related occupation (e.g., secretary, clerk, mail carrier)

Sales occupation (e.g., sales associate, demonstrator, agent, broker)

Service occupation (e.g., police officer, cook, hairdresser)

Skilled craft or related occupation (e.g., carpenter, repair technician, telephone line worker)

Equipment / vehicle operator or related occupation (e.g., driver, railroad brakeman, sewer worker)

Laborer (e.g., helper, longshoreman, warehouse worker)

Farmer (e.g., owner, manager, operator, tenant)

Member of the military

Homemaker

Student

Under school age

Not previously employed

Unknown

Other

Specify other occupation:251

What is the recipient’s current or most recent work status prior to illness?252

Full time

Part time, by choice and not due to illness

Part time, due to illness

Unemployed, by choice and not due to illness

Unemployed, due to illness

Medical disability

Retired

Unknown

What is the highest educational grade the recipient completed?253

No primary education / under school age: No schooling (US Equivalent: Less than 1st Grade Education)

Less than primary or elementary education: Some formal schooling, but less than a complete primary or elementary education (US Equivalent: More than 1st grade
education, but less than 6th grade education)

Primary or elementary education: Beginning at age 5-7 and continuing for about 4-6 years (US Equivalent: Starts with 1st grade and ends with 6th grade)

Lower secondary education: Beginning at about age 11-12 and continuing for about 2-3 years (US Equivalent: Starts with 7th grade and typically ends with 9th grade)

Upper secondary education: Beginning at about age 15-16 and continuing for about 3 years (US Equivalent: Starts with 10th grade and ends with 12th grade)

Post-secondary, non-tertiary education: Programs lasting 6 months - 2 years (US Equivalent: Vocational programs of study)

Tertiary education, Type A: Programs that provide education that is largely theoretical, lasting 3-4 years (US Equivalent: Includes university programs that last 4 years and
lead to the award of a bachelor's degree, and university programs that lead to a master's degree)

Tertiary education, Type B: Programs that focus on practical, technical or occupational skills with a minimum duration of 2 years of full-time enrollment (US Equivalent:
Programs typically offered at community colleges that lead to an associate's degree)

Advanced research qualification: Programs that lead to the award of an advanced post-graduate degree, such as a Ph.D. (US Equivalent: Programs devoted to advanced
study and original research)

Is the recipient currently in school, or was enrolled prior to illness?

yes no Unknown

254

Is the recipient covered by health insurance?

yes no

255

Government-sponsored Medicaid

yes no

256

(U.S.)

Government-sponsored Medicare

yes no

257

(U.S.)

Government-sponsored National Health Insurance

yes no

258

(non U.S.)

Government­sponsored Veteran’s Affairs / military

yes no

259

Private health insurance (premium paid by individual) or group health insurance

yes no

260

Employer-sponsored disability insurance

yes no

261

Other

yes no

262

Specify other health insurance:263

Specify the recipient’s combined household gross annual income264
(Include earnings by all family members living in the household, before taxes.) (For U.S. residents only)

Less than $20,000

$20,000–$39,999

$40,000–$59,999

$60,000–$79,999

$80,000–$99,999

$100,000 and over

Recipient declines to provide this information

Unknown

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Testing for evidence of prior viral exposure/infection

Specify radiation field:

Specify radio labeled MAb:

Specify drugs:

Specify type of health insurance:

Center: CRID: 

Form 2000 R4.0: Recipient Baseline Data

CIBMTR Form 2000 revision 4.0 last updated Monday, August 14, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 8 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Recipient ID:

Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Recipient Demographics Questions: 1 - 5

Country of primary residence1

Specify:2

State of residence of recipient:3

(for residents of USA)

Race (1) Questions: 4 - 5

Race4

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

Race detail5

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 6 - 14

Specify blood type

A B AB O

6

(For allogeneic HCTs only)

Specify Rh factor

Positive Negative

7

(For allogeneic HCTs only)

Does the recipient have a history of smoking cigarettes?

yes no Unknown

8

Has the recipient smoked cigarettes within the past year?

yes no Unknown

9

Has the recipient smoked cigarettes prior to but not during the past year?

yes no Unknown

10

Number of years

Known Unknown

11

Number of years:12

Average number of packs per day

Known Unknown

13

Average number of packs per day:14

Organ Function Prior to the Preparative Regimen (Conditioning) Questions: 15 - 38

AST (SGOT)

Known Unknown

15

16 U/L µkat/L

Date sample collected:17 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:18 U/L µkat/L

Total serum bilirubin

Known Unknown

19

20 mg/dL µmol/L

Date sample collected:21 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:22 mg/dL µmol/L

LDH

Known Unknown

23

24 U/L µkat/L

Date sample collected:25 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:26 U/L µkat/L

Serum creatinine

Known Unknown

27

28 mg/dL mmol/L µmol/L

Date sample collected:29 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:30 mg/dL mmol/L µmol/L

Total serum ferritin

Known Unknown

31

32 ng/mL (µg/L)

Date sample collected:33 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:34 ng/mL (µg/L)

Serum albumin

Known Unknown

35

36 g/dL g/L

Date sample collected:37 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:38 g/dL g/L

Hematologic Findings Prior to the Preparative Regimen (Conditioning) Questions: 39 - 54

Date CBC tested:39 __ __ __ __ - __ __- __ __

WBC

Known Unknown

40

41 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

42

43 %

Lymphocytes

Known Unknown

44

45 %

Hemoglobin

Known Unknown

46

47 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

48

Hematocrit

Known Unknown

49

50 %

Was RBC transfused < 30 days before date of test?

yes no

51

Platelets

Known Unknown

52

53 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused < 7 days before date of test?

yes no

54

Infection Questions: 55 - 75

Did the recipient have a history of clinically significant fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

55

Did the recipient have more than one fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

56

Fungal Infection (1) Questions: 57 - 63

Date of onset:57 __ __ __ __ - __ __- __ __

Select organism from list below58

210 Aspergillus, NOS

211 Aspergillus flavus

212 Aspergillus fumigatus

213 Aspergillus niger

215 Aspergillus terreus

214 Aspergillus ustus

270 Blastomyces (dermatitidis)

201 Candida albicans

208 Candida non-albicans

271 Coccidioides (all species)

222 Cryptococcus gattii

221 Cryptococcus neoformans

230 Fusarium (all species)

261 Histoplasma (capsulatum)

241 Mucorales (all species)

260 Pneumocystis (PCP / PJP)

242 Rhizopus (all species)

272 Scedosporium (all species)

240 Zygomycetes, NOS

503 Suspected fungal infection

Specify organism:59

Select site(s) from list below60

Select site(s) from list below61

Select site(s) from list below62

Was this fungal infection active within 2 weeks prior to the preparative regimen?

yes no

63

HTLV1 antibody

Reactive Non-reactive Inconclusive Not done

64

Cytomegalovirus antibody

Reactive Non-reactive Inconclusive Not done

65

Anti-EBV (Epstein-Barr virus antibody)

Positive Negative Inconclusive Not done

66

Hepatitis B surface antibody

Reactive Non-reactive Inconclusive Not done

67

Anti HBc: (hepatitis B core antibody)68

Reactive -For hepatitis tests that have a reactive result, also complete HEP form. 

Non-reactive

Not done

HBsAg: (hepatitis B surface antigen)69

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Not done

Hepatitis B — DNA70

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Anti-HCV: (hepatitis C antibody)71

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis C – NAT72

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis A antibody

Reactive Non-reactive Inconclusive Not done

73

HIV antibody

Positive Negative Inconclusive Not done Not reported

74

HIV – NAT

Positive Negative Inconclusive Not done Not reported

75

Pre-HCT Preparative Regimen (Conditioning) Questions: 76 - 247

Was a pre-HCT preparative regimen given?

yes no

76

Specify protocol intent77

(check only one) (Allogeneic HCTs only)

all agents given as outpatient

some, but not all, agents given as inpatient

all agents given as inpatient

Date pre-HCT preparative regimen
(irradiation or drugs) began:

78 __ __ __ __ - __ __- __ __

Use the earliest date from questions 82 (radiation) or 109-176 and 193-241 (systemic therapy).  Additional radiation and/or intrathecal
chemotherapy start dates may be prior to the date the preparative regimen began.  

Was irradiation performed as part of the pre-HCT preparative regimen?

yes no

79

What was the radiation field?80

total body

total body by tomotherapy

total lymphoid or nodal regions

thoracoabdominal region

Total dose:81

(dose per fraction x total number of fractions)

Gy cGy

Date started:82 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

83

Dose per fraction:84 Gy cGy

Number of days:85

(include "rest" days)

Total number of fractions:86

Was additional radiation given to other sites within 14 days of the pre-HCT preparative regimen?

yes no

87

CNS

yes no

88

Total dose:89 Gy cGy

Date started:90 __ __ __ __ - __ __- __ __

Gonadal

yes no

91

Total dose:92 Gy cGy

Date started:93 __ __ __ __ - __ __- __ __

Splenic

yes no

94

Total dose:95 Gy cGy

Date started:96 __ __ __ __ - __ __- __ __

Site of residual tumor

yes no

97

Total dose:98 Gy cGy

Date started:99 __ __ __ __ - __ __- __ __

Specify site:100

Other site

yes no

101

Total dose:102 Gy cGy

Date started:103 __ __ __ __ - __ __- __ __

Specify other site:104

Were drugs given for pre-HCT preparative regimen?

yes no

105

Dosing body weight used for pre-HCT preparative regimen (adjusted body weight):106 pounds kilograms

ALG, ALS, ATG, ATS

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Specify source

Horse Rabbit Other

110

Specify other source:111

Anthracycline

yes no

112

Daunorubicin

yes no

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

116

Total dose:117 mg

Date started:118 __ __ __ __ - __ __- __ __

Idarubicin

yes no

119

Total dose:120 mg

Date started:121 __ __ __ __ - __ __- __ __

Rubidazone

yes no

122

Total dose:123 mg

Date started:124 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

125

Total dose:126 mg

Date started:127 __ __ __ __ - __ __- __ __

Specify other anthracycline:128

Bleomycin (BLM, Blenoxane)

yes no

129

Total dose:130 mg

Date started:131 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

135

Carboplatin

yes no

136

Total dose:137 mg

Date started:138 __ __ __ __ - __ __- __ __

Cisplatin (Platinol, CDDP)

yes no

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

145

(excluding anti-nausea medication)

Methylprednisolone (Solu-Medrol)

yes no

146

Total dose:147 mg

Date started:148 __ __ __ __ - __ __- __ __

Prednisone

yes no

149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Specify other corticosteroid:158

Cyclophosphamide (Cytoxan)

yes no

159

Total dose:160 mg

Date started:161 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

162

Total dose:163 mg

Date started:164 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

165

Total dose:166 mg

Date started:167 __ __ __ __ - __ __- __ __

Fludarabine

yes no

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Intrathecal therapy

yes no

177

Intrathecal cytarabine (IT Ara-C)

yes no

178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

184

Total dose:185 mg

Date started:186 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

187

Total dose:188 mg

Date started:189 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:190

Melphalan (L-Pam)

yes no

191

Total dose:192 mg

Date started:193 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

194

Mitoxantrone (Novantrone)

yes no

195

Total dose:196 mg

Date started:197 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

198

Radio labeled MAb

yes no

199

Total dose of radioactive component:200 mCi MBq

Date started:201 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

202

Ibritumomab tiuxetan (Zevalin)

yes no

203

Other radio labeled MAb

yes no

204

Specify other radio labeled MAb:205

Alemtuzumab (Campath)

yes no

206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

209

Total dose:210 mg

Date started:211 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

212

Total dose:213 mg

Date started:214 __ __ __ __ - __ __- __ __

Other MAb

yes no

215

Total dose:216 mg

Date started:217 __ __ __ __ - __ __- __ __

Specify other MAb:218

Nitrosourea

yes no

219

Carmustine (BCNU)

yes no

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Specify other nitrosourea:229

Paclitaxel (Taxol, Xyotax)

yes no

230

Total dose:231 mg

Date started:232 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Thiotepa

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Other drug

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Specify other drug:242

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

243

Busulfan

yes no

244

Carboplatin

yes no

245

Other drug

yes no

246

Specify other drug:247

Socioeconomic Information Questions: 248 - 264

Is the recipient an adult (18 years of age or older) or emancipated minor?

yes no

248

Specify the recipient’s marital status249

single, never married

married or living with a partner

separated

divorced

widowed

Unknown

Specify the category which best describes the recipient’s current occupation250
(If the recipient is not currently employed, check the box which best describes his/her last job.)

Professional, technical, or related occupation (e.g., teacher/professor, nurse/physician, lawyer, engineer)

Manager, administrator, or proprietor (e.g., sales manager, real estate agent, postmaster)

Clerical or related occupation (e.g., secretary, clerk, mail carrier)

Sales occupation (e.g., sales associate, demonstrator, agent, broker)

Service occupation (e.g., police officer, cook, hairdresser)

Skilled craft or related occupation (e.g., carpenter, repair technician, telephone line worker)

Equipment / vehicle operator or related occupation (e.g., driver, railroad brakeman, sewer worker)

Laborer (e.g., helper, longshoreman, warehouse worker)

Farmer (e.g., owner, manager, operator, tenant)

Member of the military

Homemaker

Student

Under school age

Not previously employed

Unknown

Other

Specify other occupation:251

What is the recipient’s current or most recent work status prior to illness?252

Full time

Part time, by choice and not due to illness

Part time, due to illness

Unemployed, by choice and not due to illness

Unemployed, due to illness

Medical disability

Retired

Unknown

What is the highest educational grade the recipient completed?253

No primary education / under school age: No schooling (US Equivalent: Less than 1st Grade Education)

Less than primary or elementary education: Some formal schooling, but less than a complete primary or elementary education (US Equivalent: More than 1st grade
education, but less than 6th grade education)

Primary or elementary education: Beginning at age 5-7 and continuing for about 4-6 years (US Equivalent: Starts with 1st grade and ends with 6th grade)

Lower secondary education: Beginning at about age 11-12 and continuing for about 2-3 years (US Equivalent: Starts with 7th grade and typically ends with 9th grade)

Upper secondary education: Beginning at about age 15-16 and continuing for about 3 years (US Equivalent: Starts with 10th grade and ends with 12th grade)

Post-secondary, non-tertiary education: Programs lasting 6 months - 2 years (US Equivalent: Vocational programs of study)

Tertiary education, Type A: Programs that provide education that is largely theoretical, lasting 3-4 years (US Equivalent: Includes university programs that last 4 years and
lead to the award of a bachelor's degree, and university programs that lead to a master's degree)

Tertiary education, Type B: Programs that focus on practical, technical or occupational skills with a minimum duration of 2 years of full-time enrollment (US Equivalent:
Programs typically offered at community colleges that lead to an associate's degree)

Advanced research qualification: Programs that lead to the award of an advanced post-graduate degree, such as a Ph.D. (US Equivalent: Programs devoted to advanced
study and original research)

Is the recipient currently in school, or was enrolled prior to illness?

yes no Unknown

254

Is the recipient covered by health insurance?

yes no

255

Government-sponsored Medicaid

yes no

256

(U.S.)

Government-sponsored Medicare

yes no

257

(U.S.)

Government-sponsored National Health Insurance

yes no

258

(non U.S.)

Government­sponsored Veteran’s Affairs / military

yes no

259

Private health insurance (premium paid by individual) or group health insurance

yes no

260

Employer-sponsored disability insurance

yes no

261

Other

yes no

262

Specify other health insurance:263

Specify the recipient’s combined household gross annual income264
(Include earnings by all family members living in the household, before taxes.) (For U.S. residents only)

Less than $20,000

$20,000–$39,999

$40,000–$59,999

$60,000–$79,999

$80,000–$99,999

$100,000 and over

Recipient declines to provide this information

Unknown

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Testing for evidence of prior viral exposure/infection

Specify radiation field:

Specify radio labeled MAb:

Specify drugs:

Specify type of health insurance:

Center: CRID: 

Form 2000 R4.0: Recipient Baseline Data

CIBMTR Form 2000 revision 4.0 last updated Monday, August 14, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 9 / 10



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Recipient ID:

Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Recipient Demographics Questions: 1 - 5

Country of primary residence1

Specify:2

State of residence of recipient:3

(for residents of USA)

Race (1) Questions: 4 - 5

Race4

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

Race detail5

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning) Questions: 6 - 14

Specify blood type

A B AB O

6

(For allogeneic HCTs only)

Specify Rh factor

Positive Negative

7

(For allogeneic HCTs only)

Does the recipient have a history of smoking cigarettes?

yes no Unknown

8

Has the recipient smoked cigarettes within the past year?

yes no Unknown

9

Has the recipient smoked cigarettes prior to but not during the past year?

yes no Unknown

10

Number of years

Known Unknown

11

Number of years:12

Average number of packs per day

Known Unknown

13

Average number of packs per day:14

Organ Function Prior to the Preparative Regimen (Conditioning) Questions: 15 - 38

AST (SGOT)

Known Unknown

15

16 U/L µkat/L

Date sample collected:17 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:18 U/L µkat/L

Total serum bilirubin

Known Unknown

19

20 mg/dL µmol/L

Date sample collected:21 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:22 mg/dL µmol/L

LDH

Known Unknown

23

24 U/L µkat/L

Date sample collected:25 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:26 U/L µkat/L

Serum creatinine

Known Unknown

27

28 mg/dL mmol/L µmol/L

Date sample collected:29 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:30 mg/dL mmol/L µmol/L

Total serum ferritin

Known Unknown

31

32 ng/mL (µg/L)

Date sample collected:33 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:34 ng/mL (µg/L)

Serum albumin

Known Unknown

35

36 g/dL g/L

Date sample collected:37 __ __ __ __ - __ __- __ __

Upper limit of normal for your institution:38 g/dL g/L

Hematologic Findings Prior to the Preparative Regimen (Conditioning) Questions: 39 - 54

Date CBC tested:39 __ __ __ __ - __ __- __ __

WBC

Known Unknown

40

41 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

42

43 %

Lymphocytes

Known Unknown

44

45 %

Hemoglobin

Known Unknown

46

47 g/dL g/L mmol/L

Was RBC transfused < 30 days before date of test?

yes no

48

Hematocrit

Known Unknown

49

50 %

Was RBC transfused < 30 days before date of test?

yes no

51

Platelets

Known Unknown

52

53 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused < 7 days before date of test?

yes no

54

Infection Questions: 55 - 75

Did the recipient have a history of clinically significant fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

55

Did the recipient have more than one fungal infection (documented or suspected) at any time prior to the preparative regimen?

yes no

56

Fungal Infection (1) Questions: 57 - 63

Date of onset:57 __ __ __ __ - __ __- __ __

Select organism from list below58

210 Aspergillus, NOS

211 Aspergillus flavus

212 Aspergillus fumigatus

213 Aspergillus niger

215 Aspergillus terreus

214 Aspergillus ustus

270 Blastomyces (dermatitidis)

201 Candida albicans

208 Candida non-albicans

271 Coccidioides (all species)

222 Cryptococcus gattii

221 Cryptococcus neoformans

230 Fusarium (all species)

261 Histoplasma (capsulatum)

241 Mucorales (all species)

260 Pneumocystis (PCP / PJP)

242 Rhizopus (all species)

272 Scedosporium (all species)

240 Zygomycetes, NOS

503 Suspected fungal infection

Specify organism:59

Select site(s) from list below60

Select site(s) from list below61

Select site(s) from list below62

Was this fungal infection active within 2 weeks prior to the preparative regimen?

yes no

63

HTLV1 antibody

Reactive Non-reactive Inconclusive Not done

64

Cytomegalovirus antibody

Reactive Non-reactive Inconclusive Not done

65

Anti-EBV (Epstein-Barr virus antibody)

Positive Negative Inconclusive Not done

66

Hepatitis B surface antibody

Reactive Non-reactive Inconclusive Not done

67

Anti HBc: (hepatitis B core antibody)68

Reactive -For hepatitis tests that have a reactive result, also complete HEP form. 

Non-reactive

Not done

HBsAg: (hepatitis B surface antigen)69

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Not done

Hepatitis B — DNA70

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Anti-HCV: (hepatitis C antibody)71

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis C – NAT72

Reactive -For hepatitis tests that have a reactive result, also complete HEP form.

Non-reactive

Inconclusive

Not done

Hepatitis A antibody

Reactive Non-reactive Inconclusive Not done

73

HIV antibody

Positive Negative Inconclusive Not done Not reported

74

HIV – NAT

Positive Negative Inconclusive Not done Not reported

75

Pre-HCT Preparative Regimen (Conditioning) Questions: 76 - 247

Was a pre-HCT preparative regimen given?

yes no

76

Specify protocol intent77

(check only one) (Allogeneic HCTs only)

all agents given as outpatient

some, but not all, agents given as inpatient

all agents given as inpatient

Date pre-HCT preparative regimen
(irradiation or drugs) began:

78 __ __ __ __ - __ __- __ __

Use the earliest date from questions 82 (radiation) or 109-176 and 193-241 (systemic therapy).  Additional radiation and/or intrathecal
chemotherapy start dates may be prior to the date the preparative regimen began.  

Was irradiation performed as part of the pre-HCT preparative regimen?

yes no

79

What was the radiation field?80

total body

total body by tomotherapy

total lymphoid or nodal regions

thoracoabdominal region

Total dose:81

(dose per fraction x total number of fractions)

Gy cGy

Date started:82 __ __ __ __ - __ __- __ __

Was the radiation fractionated?

yes no

83

Dose per fraction:84 Gy cGy

Number of days:85

(include "rest" days)

Total number of fractions:86

Was additional radiation given to other sites within 14 days of the pre-HCT preparative regimen?

yes no

87

CNS

yes no

88

Total dose:89 Gy cGy

Date started:90 __ __ __ __ - __ __- __ __

Gonadal

yes no

91

Total dose:92 Gy cGy

Date started:93 __ __ __ __ - __ __- __ __

Splenic

yes no

94

Total dose:95 Gy cGy

Date started:96 __ __ __ __ - __ __- __ __

Site of residual tumor

yes no

97

Total dose:98 Gy cGy

Date started:99 __ __ __ __ - __ __- __ __

Specify site:100

Other site

yes no

101

Total dose:102 Gy cGy

Date started:103 __ __ __ __ - __ __- __ __

Specify other site:104

Were drugs given for pre-HCT preparative regimen?

yes no

105

Dosing body weight used for pre-HCT preparative regimen (adjusted body weight):106 pounds kilograms

ALG, ALS, ATG, ATS

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Specify source

Horse Rabbit Other

110

Specify other source:111

Anthracycline

yes no

112

Daunorubicin

yes no

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

116

Total dose:117 mg

Date started:118 __ __ __ __ - __ __- __ __

Idarubicin

yes no

119

Total dose:120 mg

Date started:121 __ __ __ __ - __ __- __ __

Rubidazone

yes no

122

Total dose:123 mg

Date started:124 __ __ __ __ - __ __- __ __

Other anthracycline

yes no

125

Total dose:126 mg

Date started:127 __ __ __ __ - __ __- __ __

Specify other anthracycline:128

Bleomycin (BLM, Blenoxane)

yes no

129

Total dose:130 mg

Date started:131 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

135

Carboplatin

yes no

136

Total dose:137 mg

Date started:138 __ __ __ __ - __ __- __ __

Cisplatin (Platinol, CDDP)

yes no

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

145

(excluding anti-nausea medication)

Methylprednisolone (Solu-Medrol)

yes no

146

Total dose:147 mg

Date started:148 __ __ __ __ - __ __- __ __

Prednisone

yes no

149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Other corticosteroid

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Specify other corticosteroid:158

Cyclophosphamide (Cytoxan)

yes no

159

Total dose:160 mg

Date started:161 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

162

Total dose:163 mg

Date started:164 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

165

Total dose:166 mg

Date started:167 __ __ __ __ - __ __- __ __

Fludarabine

yes no

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Ifosfamide

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Intrathecal therapy

yes no

177

Intrathecal cytarabine (IT Ara-C)

yes no

178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

yes no

184

Total dose:185 mg

Date started:186 __ __ __ __ - __ __- __ __

Other intrathecal drug

yes no

187

Total dose:188 mg

Date started:189 __ __ __ __ - __ __- __ __

Specify other intrathecal drug:190

Melphalan (L-Pam)

yes no

191

Total dose:192 mg

Date started:193 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

194

Mitoxantrone (Novantrone)

yes no

195

Total dose:196 mg

Date started:197 __ __ __ __ - __ __- __ __

Monoclonal antibody

yes no

198

Radio labeled MAb

yes no

199

Total dose of radioactive component:200 mCi MBq

Date started:201 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

202

Ibritumomab tiuxetan (Zevalin)

yes no

203

Other radio labeled MAb

yes no

204

Specify other radio labeled MAb:205

Alemtuzumab (Campath)

yes no

206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

209

Total dose:210 mg

Date started:211 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti CD33)

yes no

212

Total dose:213 mg

Date started:214 __ __ __ __ - __ __- __ __

Other MAb

yes no

215

Total dose:216 mg

Date started:217 __ __ __ __ - __ __- __ __

Specify other MAb:218

Nitrosourea

yes no

219

Carmustine (BCNU)

yes no

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Other nitrosourea

yes no

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Specify other nitrosourea:229

Paclitaxel (Taxol, Xyotax)

yes no

230

Total dose:231 mg

Date started:232 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Thiotepa

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Other drug

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Specify other drug:242

Were pharmacokinetics performed to determine preparative regimen drug dosing?

yes no

243

Busulfan

yes no

244

Carboplatin

yes no

245

Other drug

yes no

246

Specify other drug:247

Socioeconomic Information Questions: 248 - 264

Is the recipient an adult (18 years of age or older) or emancipated minor?

yes no

248

Specify the recipient’s marital status249

single, never married

married or living with a partner

separated

divorced

widowed

Unknown

Specify the category which best describes the recipient’s current occupation250
(If the recipient is not currently employed, check the box which best describes his/her last job.)

Professional, technical, or related occupation (e.g., teacher/professor, nurse/physician, lawyer, engineer)

Manager, administrator, or proprietor (e.g., sales manager, real estate agent, postmaster)

Clerical or related occupation (e.g., secretary, clerk, mail carrier)

Sales occupation (e.g., sales associate, demonstrator, agent, broker)

Service occupation (e.g., police officer, cook, hairdresser)

Skilled craft or related occupation (e.g., carpenter, repair technician, telephone line worker)

Equipment / vehicle operator or related occupation (e.g., driver, railroad brakeman, sewer worker)

Laborer (e.g., helper, longshoreman, warehouse worker)

Farmer (e.g., owner, manager, operator, tenant)

Member of the military

Homemaker

Student

Under school age

Not previously employed

Unknown

Other

Specify other occupation:251

What is the recipient’s current or most recent work status prior to illness?252

Full time

Part time, by choice and not due to illness

Part time, due to illness

Unemployed, by choice and not due to illness

Unemployed, due to illness

Medical disability

Retired

Unknown

What is the highest educational grade the recipient completed?253

No primary education / under school age: No schooling (US Equivalent: Less than 1st Grade Education)

Less than primary or elementary education: Some formal schooling, but less than a complete primary or elementary education (US Equivalent: More than 1st grade
education, but less than 6th grade education)

Primary or elementary education: Beginning at age 5-7 and continuing for about 4-6 years (US Equivalent: Starts with 1st grade and ends with 6th grade)

Lower secondary education: Beginning at about age 11-12 and continuing for about 2-3 years (US Equivalent: Starts with 7th grade and typically ends with 9th grade)

Upper secondary education: Beginning at about age 15-16 and continuing for about 3 years (US Equivalent: Starts with 10th grade and ends with 12th grade)

Post-secondary, non-tertiary education: Programs lasting 6 months - 2 years (US Equivalent: Vocational programs of study)

Tertiary education, Type A: Programs that provide education that is largely theoretical, lasting 3-4 years (US Equivalent: Includes university programs that last 4 years and
lead to the award of a bachelor's degree, and university programs that lead to a master's degree)

Tertiary education, Type B: Programs that focus on practical, technical or occupational skills with a minimum duration of 2 years of full-time enrollment (US Equivalent:
Programs typically offered at community colleges that lead to an associate's degree)

Advanced research qualification: Programs that lead to the award of an advanced post-graduate degree, such as a Ph.D. (US Equivalent: Programs devoted to advanced
study and original research)

Is the recipient currently in school, or was enrolled prior to illness?

yes no Unknown

254

Is the recipient covered by health insurance?

yes no

255

Government-sponsored Medicaid

yes no

256

(U.S.)

Government-sponsored Medicare

yes no

257

(U.S.)

Government-sponsored National Health Insurance

yes no

258

(non U.S.)

Government­sponsored Veteran’s Affairs / military

yes no

259

Private health insurance (premium paid by individual) or group health insurance

yes no

260

Employer-sponsored disability insurance

yes no

261

Other

yes no

262

Specify other health insurance:263

Specify the recipient’s combined household gross annual income264
(Include earnings by all family members living in the household, before taxes.) (For U.S. residents only)

Less than $20,000

$20,000–$39,999

$40,000–$59,999

$60,000–$79,999

$80,000–$99,999

$100,000 and over

Recipient declines to provide this information

Unknown

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Testing for evidence of prior viral exposure/infection

Specify radiation field:

Specify radio labeled MAb:

Specify drugs:

Specify type of health insurance:

Center: CRID: 

Form 2000 R4.0: Recipient Baseline Data

CIBMTR Form 2000 revision 4.0 last updated Monday, August 14, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 10 / 10